Introduction
============

The DNA-damaging agent, *cis*-diamminedichloroplatinum (II), cisplatin, is used extensively as a chemotherapeutic drug. In particular, it is successfully employed to treat ovarian and testicular carcinomas, as well as a range of other solid tumours ([@b1-cin-6-0315]; [@b29-cin-6-0315]). However, dose-limiting toxic side effects and the occurrence of both acquired and intrinsic drug resistance in cells impose great limitations on cisplatin chemotherapy ([@b73-cin-6-0315]; [@b140-cin-6-0315]). While concerted efforts have been made towards developing cisplatin analogues with improved chemotherapeutic efficacy and reduced toxic side effects, only a few compounds have been clinically registered---the most notable of these being carboplatin and oxaliplatin ([@b55-cin-6-0315]).

A major factor contributing to the current status of rationally designed analogues is a relatively poor understanding of the specific molecular events associated with cisplatin-induced tumour cell death. Although its detailed mechanism of action is presently unclear, it is generally thought that the covalent binding of cisplatin to cellular DNA and subsequent formation of bulky DNA adducts, mediate the cytotoxicity of this anti-cancer agent ([@b129-cin-6-0315]; [@b165-cin-6-0315]). Intra-strand DNA cross-links are the most common adducts formed, although inter-strand DNA cross-links and DNA-protein cross-links can also occur ([@b41-cin-6-0315]; [@b90-cin-6-0315]). The intra-strand DNA lesions preferentially form between the N-7 of adjacent guanine residues, inhibiting the passage of polymerases and thus interfering with DNA replication and RNA transcription inside target cells ([@b25-cin-6-0315]; [@b109-cin-6-0315]; [@b110-cin-6-0315]; [@b128-cin-6-0315]). While the general inhibition of RNA synthesis reduces the mRNA levels of many genes, an active cellular response to cisplatin damage can influence gene expression both positively and negatively and to varying extents, depending on the promoter ([@b36-cin-6-0315]).

The active response to such drug-induced DNA damage consists of two key processes. These include the repair of DNA damage through the removal of cisplatin adducts and, where repair cannot be carried out successfully, the induction of cell death via apoptosis. While DNA repair and apoptotic pathways are considered to play the most significant role in determining cisplatin's cytotoxic effect, various non-specific events associated with the drug-DNA interaction should also be taken into account. These non-specific events arise as consequences of cisplatin-DNA adduct formation and the overall inhibition of DNA and RNA synthesis. In addition, altered gene expression could also result from cisplatin-protein interactions ([@b124-cin-6-0315]) and the sequestration of transcription factors by cisplatin-DNA adducts. At present, little is known about the extent to which each of these active and non-specific responses contribute to cisplatin-induced cell death. This issue is addressed in the main aim of this work, which is to determine whether the regulation of specific genes in response to cisplatin treatment is crucial to the drug's anti-tumour activity.

Oligonucleotide microarrays containing approximately nineteen thousand human genes were used to examine the broad effect of cisplatin on gene expression in human foreskin fibroblasts. The response of such a non-cancer cell line to DNA damage was considered to be particularly significant since most toxic side effects are due to the exposure of normal cells to the anti-tumour drug during chemotherapy. The gene expression profiles derived from these cells indicated that many genes consistently exhibited altered gene expression patterns due to cisplatin treatment. Rigorous methods for analysing the resulting microarray data were developed. Thorough normalisation techniques and a statistically robust procedure for estimating the significance of gene expression changes were implemented via the statistical computing environment, "R". Using the software package, EASE, a method for exploring the biological themes among differentially expressed transcripts was also investigated. An attempt to clarify whether any of these molecular events are crucial to cisplatin's anti-tumour activity was made by constructing similar expression profiles for the clinically inactive cisplatin isomer, transplatin ([Fig. 1](#f1-cin-6-0315){ref-type="fig"}). Both compounds were found to consistently induce a common subset of gene responses in fibroblasts. However, thorough one- and two-sample statistical comparisons also indicated that several genes had significantly different expression levels in cisplatin-treated cells compared to transplatin-treated cells. The identification of gene expression responses unique to clinically active compounds, such as cisplatin, could have a range of implications on the design and development of improved chemotherapeutics.

Materials and Methods
=====================

Materials
---------

Cisplatin, transplatin and Tri-Reagent were purchased from Sigma. Cell culture reagents and Superscript (II) Reverse Transcriptase were obtained from Invitrogen. Alamar Blue reagent was purchased through Astral Scientific. RNeasy columns were obtained from Qiagen. Cy3 and Cy5 mono-reactive fluorescent dyes were purchased from Amersham Biosciences. Human 19K oligonucleotide microarrays were produced by and purchased from The Clive and Vera Ramaciotti Centre for Gene Function Analysis, University of NSW.

Cell Culture Conditions
-----------------------

The non-transformed human foreskin fibroblast cell line, FFbw002, was kindly donated by Noel Whitaker. Cells were grown in RPMI (Rosewell Park Memorial Institute) medium supplemented with 10% fetal bovine serum and maintained at 37 °C and 5% CO2 in a humidified incubator. Fibroblasts in log-phase growth were harvested prior to sub-culturing and drug treatment using mild trypsinisation.

Cytotoxicity Assay
------------------

Cytotoxicity determinations for cisplatin and transplatin were performed using an Alamar Blue^™^ assay. FFbw002 Human foreskin fibroblasts were seeded at a density of 2 × 10^5^ cells/ml in 96-well, flat-bottomed microtitre plates in 100 μl of RPMI medium. Drugs (diluted in DMF) and controls were administered to cells in 100 μl of RPMI to give the final concentrations indicated: cisplatin (0.1mM to 100mM), transplatin (0.1 μM to 100 μM) and DMF (0.01% to 8% (v/v)). At least three replicates were performed for each administration. The plates were incubated at 37 °C in a humidified cell culture chamber with 5% CO~2~ for 5 hours. Twenty μl of Alamar Blue^™^ reagent was then added to each well and the plates were incubated for a further 3 hours. At this time, absorbance readings of the plates were immediately recorded using a Benchmark plate-reader with a sample wavelength of 570 nm and a reference of 595 nm. Following this eight-hour time point, plates were returned to the incubator and further absorbance readings were taken at 24 hours. Cell survival in the presence of drug was expressed as a percentage of cell growth in the drug-free DMF control corresponding to the% DMF in the drug treatment.

Drug Treatment and Total RNA Extraction
---------------------------------------

Harvested fibroblasts were incubated at a concentration of approximately 5 × 10^6^ cells/ml RPMI medium, with varying concentrations of cisplatin or transplatin (each diluted in DMF), for 5 hours at 37 °C with 5% CO~2~. Total RNA was then isolated from cells using Tri-Reagent and the accompanying protocol for extracting total RNA from cultured cells (issued by Sigma). The integrity of total RNA was assessed using 1% agarose gel electrophoresis and its approximate concentration and purity estimated via UV spectrophotometry.

cDNA Synthesis and Hybridisation
--------------------------------

cDNA was synthesised using approximately 50 μg of total RNA in an oligo-dT(20mer)-primed reverse transcription reaction with Superscript II Reverse Transcriptase (Invitrogen). RNA was combined with 8 μl of 5× First Strand Superscript II Buffer (Invitrogen), 0.4nmol oligo-dT~20~, 10 μM DTT and made up to 32.2 μl with RNase-free H~2~O. Reactions were incubated for 5 minutes at 65 °C followed by 5 minutes at 42 °C. While at 42 °C, dATP, dGTP and dCTP nucleotides were added at a final concentration of 0.5 μM each, along with dTTP at 0.16 μM, aa(aminoalyl)-dUTP at 0.34 μM and 2 μl Superscript II Reverse Transcriptase. Reactions were then incubated for a further 2.5 hours at 42 °C. RNA was hydrolysed with the addition of 4ml of 50mM EDTA (pH8) and 2 μl of 10M NaOH to each sample, followed by an incubation of 20 minutes at 65 C. Reactions were neutralised with 4 μl of 5M acetic acid and then each sample was purified using a separate QIAquick PCR purification column (Qiagen). To couple mono-reactive fluorescent Cy-dyes (Amersham Biosciences) to the aminoalyl-dUTP moieties in target cDNA molecules, 9 μl of 0.1M NaHCO~3~ (pH9) and 2 μl of Cy5 (control samples) or Cy3 (drug-treated samples) were mixed with the appropriate samples. These reactions were left to incubate in a dark environment for 45 minutes at room temperature and then purified as above, using a separate QIAquick PCR purification column (Qiagen) for each sample. Hybridisation buffer was prepared with yeast tRNA (Sigma) at approximately 0.5 mg/ml and calf thymus DNA (Sigma) at approximately 0.5 mg/ml in DIG Easy Hyb (Roche). Concentrated Cy5(control) and Cy3(drug-treated) cDNA samples to be compared were combined directly with hybridisation buffer to a final volume of approximately 92 μl, heated for 5 minutes at 65 C and then allowed to cool to room temperature. Hybridisation mixtures were applied directly to microarray slides (Human 19K oligonucleotide arrays), each covered with a LifterSlip^™^ coverglass (ProSciTech) and then hybridised at 37 °C overnight (approximately 16 hours) in a humidified custom-made hybridisation chamber. LifterSlips^™^ were removed in 1 × SSC and slides washed three times in 1 × SSC/0.1% SDS at 50 °C. A final rinse in 1 × SSC was immediately followed by 10 minutes of centrifugation at 500 g to dry slides in preparation for scanning.

Microarray Scanning, Data Acquisition and Processing
----------------------------------------------------

Microarrays were scanned using an Axon 4000A laser-based scanner and image data was acquired through associated GenePix Pro 3.0 software. Further data manipulation and statistical analyses (see below) were undertaken in the R statistical computing environment ([www.r-project.org](www.r-project.org)) with additional microarray-specific R-packages available from the BioConductor project ([www.bioconductor.org](www.bioconductor.org)). The R-function, *marrayGUI*, constructed by Mr Chris Bye (Westmead Millennium Institute) was used to input data into the R environment. Preliminary data processing involved the assignment of spot quality 'weights' to all data points. A "Robust Spline" method of intra-array normalisation (*limma* package in BioConductor), which utilises the spot quality weights determined above, was then applied to each slide. This approach accounts for both spatial- and intensity-dependent biases by fitting regression splines through data from individual print-tip groups and employing Empirical Bayes methods to shrink the print-tip curves towards a common value. Compared to standard "Print-tip Loess" normalisation procedures, such a technique is believed to introduce less "noise" into fairly good quality arrays that have little spatial variation. At this stage, unreliable data from spots with low quality weights due to low signal intensities or high spot background intensities was mostly filtered out so as to be excluded from further statistical analyses.

Statistical Evaluation of Differential Gene Expression
------------------------------------------------------

Functions within the *limma* package in BioConductor were firstly employed to calculate a log-odds of differential expression (B-statistic) for each gene. This involved the fitting of gene-wise linear models through selected data and Empirical Bayes moderation of corresponding t-statistics. 'One-' and 'Two-sample' experimental design matrices were structured to allow the simultaneous assessment of differential expression within and between experimental conditions (microarray groups), respectively. The magnitudes of resulting B-statistics were then used to rank genes in order of evidence for differential expression. Transcripts considered to have a significant level of differential expression *within* a single test comparison (e.g. control vs treatment 1), were those highly ranked according to 'one-sample' B-statistic magnitudes and with average fold-changes greater than 1.4. Alternative procedures for multiple hypothesis testing available within the *multtest* package in BioConductor, were also investigated. In an ANOVA framework, F-statistics were calculated for each transcript using log expression ratio data from the three main test comparisons. As for the B-statistics, the magnitudes of these test-statistics were then used directly to identify transcripts most likely to be differentially expressed between the three test conditions.

Gene Categories Over-represented Among Differentially Expressed Transcripts
---------------------------------------------------------------------------

Analysis tools implemented within the software package EASE (Expression Analysis Systematic Explorer) were used to annotate differentially expressed transcripts and explore the "biological themes" of significant gene subsets. EASE is freely available through the URL <http://david.niaid.nih.gov/david/ease.htm>.

Results
=======

The human gene expression response to cisplatin treatment was investigated using transcription profiling techniques. The use of oligonucleotide microarrays permitted the gene expression levels of many genes to be monitored simultaneously.

A human foreskin fibroblast cell line was employed and gene expression profiles were compiled for both cisplatin and its clinically ineffective isomer, transplatin. The transcriptional response of fibroblasts to drugs with different anti-tumour efficiencies could then be investigated.

Alamar Blue^™^ cytotoxicity assays
----------------------------------

Fibroblasts were firstly subjected to cytotoxicity assays with cisplatin and transplatin to determine optimal treatment conditions for inducing a clinically relevant gene expression response. Fibro-blasts were initially incubated at 37°C with drugs (or without drugs or controls) for 5 hours. At this time point, t = 5 hours, Alamar Blue^™^ reagent was added to each sample. Absorbance measurements were then taken at t = 8 and 24 hour time points and used to indicate the proportion of living cells remaining in each sample. Graphs in [Figure 2](#f2-cin-6-0315){ref-type="fig"} depict the percentage cell survival values determined for fibroblasts treated with 0.1--100 μM cisplatin or transplatin for 8 and 24 hours.

The cytotoxicity assay results for this particular fibroblast cell line indicated that there was a small to moderate difference between the cytotoxic effects elicited by cisplatin and transplatin. At the 8 hour time point, cisplatin was more toxic than transplatin at concentrations up to at least 25 μM. At 100 μM doses, transplatin appeared to induce slightly higher levels of cell death. For the 24 hour time point, however, cisplatin was consistently more cytotoxic to cells at all concentrations examined. Overall, drug concentrations ranging between 0.1 and 25 μM produced relatively low levels of cell death during both incubation periods. Within this dose range, the average cell survival estimates were 90% for cisplatin treatments and 95% for transplatin treatments. At drug concentrations above 25 μM, however, the cytotoxic effect of both compounds was more apparent.

In considering these results and those of the preliminary investigations, subsequent gene expression studies were conducted using 5 hour treatments with 1 μM cisplatin or transplatin. At this concentration, the cytotoxicity assay indicated that there was a slight difference between the toxic effects of the two isomers. To allow gene expression responses to *equitoxic* drug doses to be studied, a second transplatin concentration of 25 μM was also chosen for comparison. At this 8 hour dose, transplatin's level of toxicity was approximately equivalent to that of 1 μM cisplatin. Similar differences in concentration have been required to achieve equitoxic cisplatin and transplatin doses in other studies ([@b19-cin-6-0315]; [@b133-cin-6-0315]; [@b134-cin-6-0315]). Furthermore, this concentration represented the lowest dose at which cytotoxicity levels were relatively low for both drugs.

Microarray experiments, data acquisition and normalisation
----------------------------------------------------------

All cell treatments were performed in quadruplicate. Total RNA was extracted from each cell population and used to synthesise fluorescently-labelled cDNA. cDNA samples derived from different treatments were then compared directly using human oligo-nucleotide microarrays containing approximately 19,000 human gene sequences and control elements. Microarray experiments, also carried out in quadruplicate, were performed for each of the following comparisons: DMF (control) vs 1 μM Cisplatin, DMF vs 1 μM Transplatin, DMF vs 25 μM Transplatin, 1 μM Transplatin vs 1 μM Cisplatin and 25 μM Transplatin vs 1 μM Cisplatin.

Following microarray scanning and data acquisition, raw results were processed and normalised as described in section 2.3.12. During these manipulations, the red and green fluorescence intensities were normalised relative to one another so that the green/red ratios approached an unbiased representation of relative expression levels. The ultimate aim of the normalisation process was to remove or reduce any systematic biases or errors in the results that were not due to the experimental condition(s) of interest ([@b142-cin-6-0315]). In the current study, a "Robust Spline" method of intra-array normalisation was applied to data from each microarray using the *limma* (Linear Models for Microarray Data) package in BioConductor. The incorporation of spot quality weights determined in the preprocessing step (section 2.3.12(i)) controlled the extent to which each data point contributed to the normalisation calculations. This meant that unreliable data from spots with low quality weights due to low foreground or high background intensities were filtered out and excluded from the analysis. The "Robust Spline" function also accounted for both spatial- and intensity-dependent biases in the microarray data ([@b142-cin-6-0315]; [@b167-cin-6-0315]).

'MA-plots', as described by [@b167-cin-6-0315], provided a convenient graphical means of representing the red (R) and green (G) fluorescence intensity data for each gene on the array. Within these plots, M~(y-axis)~ = log~2~(R/G) and A~(x-axis)~ = log~2~v(R × G). Thus, for each gene on the array, 'M' essentially describes the fluorescence intensity ratio, while 'A' represents the relative combined fluorescence intensity ([@b167-cin-6-0315]). [Figure 3](#f3-cin-6-0315){ref-type="fig"} shows a representative MA-plot for the normalised background-corrected data from DMF vs 1 μM Cisplatin treatment comparisons. Human gene transcripts with relatively up- or down-regulated expression levels due to cisplatin treatment are located below or above the 'M = 0' horizontal axis, respectively. In this study, MA-plots were particularly valuable in terms of identifying spot artifacts (or irregularities) and intensity-dependent trends in the log ratios (M-values). They were also employed for the purpose of monitoring and assessing the data normalisation procedures described above.

Statistical significance evaluation -- Overview
-----------------------------------------------

Having normalised the microarray data, the next step was to develop a statistically robust approach for defining differentially expressed transcripts. When examining such large sets of gene expression data, it is particularly crucial to address this issue since observed changes in expression may not always be a direct consequence of the test conditions. For example, altered expression patterns may result from variations in the data acquisition procedures or biologically insignificant fluctuations within the original cell populations that are not specifically related to the experimental conditions of interest. While many expression studies use a two-fold change in expression as the lower limit of significant gene expression changes, this approach can exclude valuable data and is not statistically flexible for use across multiple arrays. Instead, the current study adopted a statistically rigorous method for estimating and ranking the relative significance of observed gene expression changes.

Conducted within 'R', the main statistical procedure for defining differential expression implemented functions from the *limma* analysis package in BioConductor. These functions effectively facilitated the simultaneous analysis of comparisons between multiple RNA targets (that is, differentially-labeled cDNA populations). The key to this approach was a "design matrix" which was used to specify the desired treatments for comparison. This meant that data from multiple arrays could thus be examined simultaneously. The result was a log-odds of differential expression, or B-statistic, which was estimated for each gene in each treatment comparison. B-statistic magnitudes were then used to rank genes in order of evidence for differential expression.

Using the linear model approach described above, a "one-sample comparison" experimental design matrix was used to examine differential expression *within* separate microarray groups, where each 'group' represents one comparison performed on four replicate microarrays:

1.  **Group 1.** DMF vs 1 μM cisplatin

2.  **Group 2.** DMF vs 1 μM transplatin

3.  **Group 3.** DMF vs 25 μM transplatin

4.  **Group 4.** 1 μM transplatin vs 1 μM cisplatin

5.  **Group 5.** 25 μM transplatin vs 1 μM cisplatin.

B-statistics were computed for all five comparisons. Genes with the highest B-statistics thus had the highest likelihood of being differentially expressed within each group. Next, data from the first three microarray groups was combined within a "two-sample comparison" design matrix. This technique was employed to assess the extent of differential expression *between* microarray groups, and thus between treatments. For example, the simultaneous analysis of Group 1 and Group 3 data revealed over 200 genes that were highly ranked for differential expression between the 1 μM cisplatin and 25 μM transplatin treatments. Following both one- and two-sample comparison B-statistic analyses, the 'EASE' software package was employed to search for over-represented gene categories amongst differentially expressed genes. This procedure allowed the biological themes of significant gene subsets to be investigated. In the subsequent sections of this chapter, the results of B-statistic analyses and over-representation studies are presented and discussed in further detail.

One-sample comparison B-statistic analysis
------------------------------------------

One-sample comparison B-statistic analyses were successfully employed to estimate the relative significance of 'apparent' changes in gene expression levels between control and drug-treated samples. Transcripts with B-statistic values greater than zero were defined as exhibiting significantly different expression levels in response to treatment, while the highest B-statistics indicated genes with the highest likelihood of being differentially expressed. This study revealed many genes that were differentially expressed in each of the three treatments examined: 1 μM cisplatin, 1 μM and 25 μM transplatin (see [Table 1](#t1-cin-6-0315){ref-type="table"}). For example, in cisplatin-treated cells, 1227 transcripts were found to exhibit significantly higher expression levels, while 316 transcripts were classed with significantly *lower* expression levels. [Table 2](#t2-cin-6-0315){ref-type="table"} describes the first 20 known genes that were significantly up- and down-regulated in response to 1 μM cisplatin. As might be expected, many of the differentially expressed transcripts were common to cisplatin and transplatin treatments, indicating some degree of consistency in the transcriptional response to both platinum isomers. Some of the transcriptional events common to all three treatments are also indicated in [Table 2](#t2-cin-6-0315){ref-type="table"}.

Using the expression analysis program, EASE, gene annotation tools were next employed to identify gene categories that were over-represented in each differentially expressed gene subset compared to what was represented on the microarrays. Individual gene categories were also classed into one of the following gene ontology (GO) systems: molecular function, biological process or cellular component. In each analysis, the gene category with the lowest 'EASE score' was considered to be the most 'over-represented' or significant category within that subset of differentially expressed transcripts. The first 20 most over-represented gene categories among transcripts up- and down-regulated by 1mM cisplatin are shown in [Table 3](#t3-cin-6-0315){ref-type="table"}. As indicated, most of these categories were also over-represented among the significant transcripts of transplatin treatments. It is thus possible that many of the genes associated with these molecular functions and biological processes are involved in a more general response to the toxic insult.

One-sample B-statistics were also calculated for the Group 4 and Group 5 microarray data: 1 μM transplatin vs 1 μM cisplatin and 25 μM transplatin vs 1 μM cisplatin. However, this analysis largely yielded negative B-statistic values, implying that there were no significant differences between the transcriptional responses to each treatment. Another possibility was that variations between the treatment-specific gene expression profiles were of a magnitude that could not be resolved using this technique, especially in the presence of relatively large systematic errors and inherent dye biases. While dye-swapping or reciprocal labeling techniques are often employed in attempts to counteract such biases, this approach is more amenable to microarray experiments in which the differences between cDNA populations are of a higher magnitude (for example, when comparing different cell lines). In the current study, the average 'significant' drug-induced gene expression changes were only approximately two-fold relative to control (non-treated) samples (see [Table 1](#t1-cin-6-0315){ref-type="table"}). Since a key aim of this work was to study treatment-specific gene expression events, an alternative method for comparing the transcriptional responses to each treatment was investigated. For this purpose, a *two-sample* comparison B-statistic analysis was employed to contrast the 'control vs treatment' profiles already established for cisplatin and transplatin.

Two-sample comparison B-statistic analysis
------------------------------------------

The two-sample B-statistic analysis facilitated the simultaneous comparison of microarray data from two different 'control vs treatment' experiments. Through the *inter*-array comparison of samples labeled with the same dye, B-statistics were used to detect more subtle differences in the expression responses to cisplatin and transplatin exposure, without the interference of dye biases. This approach, however, failed to recognise any consistently significant differences between the expression profiles induced by 5 hour 1 μM cisplatin and transplatin treatments. This implied a very high degree of similarity between the transcriptional responses of fibroblasts to these equivocal doses of cisplatin and transplatin. In contrast, two-sample comparison B-statistics readily detected significant differences between the responses to 1 μM cisplatin and 25 μM transplatin treatments. Altogether, 105 transcripts were found to be significantly more abundant in the 1 mM cisplatin treatments while 64 transcripts were more abundant in the 25 μM transplatin treatments ([Table 1](#t1-cin-6-0315){ref-type="table"}). For many of these genes, the origin or cause of their differential response could be clarified by cross-comparing the results of the two-sample comparisons with those of the one-sample comparisons. For example, transcripts that were more abundant in cisplatin treatments could be further classified as being 'actively up-regulated by cisplatin' if they were also present among the up-regulated genes of the one-sample 'control vs 1 μM cisplatin' comparisons. An overview of this classification process is presented in [Figure 4](#f4-cin-6-0315){ref-type="fig"}. Of the 105 transcripts more abundant in cisplatin treatments, 27 were classified as being up-regulated by cisplatin ([Table 4](#t4-cin-6-0315){ref-type="table"}), 35 as being down-regulated by transplatin ([Table 5](#t5-cin-6-0315){ref-type="table"}), and 43 could not be classified into either group using the current one-sample data ([Table 6](#t6-cin-6-0315){ref-type="table"}). Of the 64 transcripts more abundant in transplatin treatments, 12 were classed as being up-regulated by transplatin ([Table 7](#t7-cin-6-0315){ref-type="table"}), 19 as being down-regulated by cisplatin ([Table 8](#t8-cin-6-0315){ref-type="table"}), and 33 did not correlate with any one-sample comparisons ([Table 9](#t9-cin-6-0315){ref-type="table"}).

Functions within EASE were also employed to detect gene categories that were significantly over-represented among the 169 transcripts differentially expressed between cisplatin and transplatin treatments. [Tables 10](#t10-cin-6-0315){ref-type="table"} and [11](#t11-cin-6-0315){ref-type="table"} show some of the most over-represented categories among transcripts found to be more abundant in 1 μM cisplatin and 25 μM transplatin treatments, respectively.

Discussion
==========

The effect of the anti-tumour drug, cisplatin, on human gene expression was investigated using microarray-based transcription profiling techniques in human cells. The transcriptional response of human fibroblasts to a clinically relevant cisplatin dose was examined in detail using human 19K microarrays. Gene expression profiles were also compiled for transplatin, the therapeutically ineffective isomer of cisplatin. Statistically robust methods for assessing the significance of apparent changes in gene expression were then investigated. The first approach permitted the identification of human gene transcripts exhibiting significantly different expression levels in drug-treated compared to control samples. A second method was then used to reveal transcripts that were differentially expressed between the three drug treatments examined. During these comparisons, a subset of 169 transcripts was found to be differentially expressed between cisplatin and transplatin treatments. Gene ontology databases were used to recognise gene categories that were comparatively over-represented among the significant transcripts, compared to what was represented on the microarrays. This allowed the biological themes of the differential responses to cisplatin and transplatin treatments to be explored and further considered with respect to anti-tumour activity.

Transcription profiling in drug-treated cells: overview
-------------------------------------------------------

Toxic stress in cells can stimulate a range of biological responses, including the transcriptional modulation of genes regulating cell survival, DNA repair and cell death. It has thus been proposed that such complex patterns of induced gene expression changes could provide considerable insight into the mechanism of action of various toxic agents (Amen et al. 2002; Munson et al. 1999; Cabal et al. 2005; Hamden et al. 2002; [@b117-cin-6-0315]). For example, the discipline of toxicogenomics seeks to exploit the complexity of this response for the purpose of generating a molecular profile or signature that is characteristic of specific toxicant exposure (reviewed by ([@b45-cin-6-0315])). Furthermore, microarray-based genomic approaches can now serve as a powerful tool for exploring the molecular pathways and cellular processes that mediate the adverse responses to a particular compound ([@b20-cin-6-0315]).

The broad aim of the microarray experiments conducted in the present study was to investigate global gene expression responses to cisplatin exposure in human cells. The first significant outcome of this project was the establishment of distinct gene expression profiles for equitoxic doses of cisplatin and transplatin, relative to solvent (DMF) controls.

The second and somewhat more challenging aim of this study was to identify gene expression events that are unique to cisplatin treatment and could play an important role in its cytotoxic mechanism. For this purpose, transcription profiles constructed for cisplatin and its clinically ineffective isomer, transplatin, were compared. Many toxic compounds will lead to the induction of genes that are unrelated to anti-tumour activity. However, the use of active and inactive anti-tumour agents permits the identification of responses that contribute to anti-tumour activity and responses that do not contribute to anti-tumour activity. When sufficient data from different agents is combined, as in the case with cisplatin and transplatin, it may be possible to differentiate generic stress responses from compound-specific events ([@b19-cin-6-0315]; [@b45-cin-6-0315]).

In order to extract accurate and informative data from this kind of gene expression study, there are several major experimental considerations that must also be addressed. One particular concern surrounds the biological system employed and its associated variables. In this project, non-transformed human foreskin fibroblasts were chosen as the initial cell type in which drug-induced gene expression profiles would be monitored. Most gene expression studies with cisplatin have been focused upon cancer cells against which cisplatin is successfully cytotoxic or ineffective due to problems of resistance ([@b24-cin-6-0315]; [@b68-cin-6-0315]; [@b88-cin-6-0315]; [@b93-cin-6-0315]; [@b113-cin-6-0315]; [@b127-cin-6-0315]; [@b154-cin-6-0315]; [@b157-cin-6-0315]; [@b166-cin-6-0315]). Since both cancer and non-cancer cells of a patient are exposed to clinical treatments, a detailed look at the response of 'normal' cells to cisplatin may provide a more balanced insight into the toxic mechanism of this drug. Also, a number of important genes are "inactivated" in many tumour cells, such as p53 and retinoblastoma ([@b64-cin-6-0315]; [@b89-cin-6-0315]; [@b99-cin-6-0315]; [@b136-cin-6-0315]; [@b161-cin-6-0315]). Insight into the effect of cisplatin on the functional versions of such genes might thus be gained via the use of non-cancer cells in gene expression studies.

Biological variables that arise from experimental design, such as dose and time of exposure to the compound, also have a large impact on the analysis and subsequent interpretation of microarray data. These factors were thus given thorough consideration in the current study via several preliminary experiments. Filter macroarray studies revealed significant changes in gene expression upon the treatment of cells with 5 hour doses of cisplatin at concentrations between 1 and 50 μM. This study focused upon a moderate set of treatment conditions and a concentration of 1 μM cisplatin was chosen, since this dose falls within clinical ranges and has also been used in other microarray-based gene expression studies with cisplatin ([@b63-cin-6-0315]). Furthermore, this dose was not found to induce high levels of cell death in fibroblasts, according to cytotoxicity assay results. While gene expression profiles have already been used to define toxicity in various biological systems ([@b21-cin-6-0315]; [@b44-cin-6-0315]; [@b159-cin-6-0315]), many of the chemical agents have been used at significantly toxic levels. It is now being recognised that more biologically relevant results are obtained under conditions of mild toxicity, particularly in the absence of any cellular or pathological changes ([@b45-cin-6-0315]). Moreover, this approach has been successfully applied to identify differentially expressed genes during inflammatory responses to hexachlorobenzene ([@b38-cin-6-0315]). Together, these observations lend further support for the final choice of treatment conditions investigated here.

In order to compare the differential effects of cisplatin and transplatin treatments, two different concentrations of the clinically ineffective isomer were examined. In addition to an equimolar dose of 1 μM, a second approximately equitoxic dose of 25 μM transplatin was also selected for comparison with 1 μM cisplatin. Similar investigations have required transplatin at various doses between 2 and 100 times the concentration of cisplatin to achieve equitoxic effects ([@b19-cin-6-0315]; [@b133-cin-6-0315]; [@b134-cin-6-0315]). In addition, at least four-fold more transplatin than cisplatin adducts have been required to significantly inhibit transcription elongation in HeLa cells ([@b98-cin-6-0315]). However, in comparing 1 μM cisplatin and 25 μM transplatin doses, it is also possible that observed differences between gene expression profiles may arise purely due to the difference in drug 'loads'. While the cytotoxicity assay indicated that relative toxicity levels were the same for these two treatments, the possibility of dose effects should also be taken into consideration. Interestingly, in the final microarray data, the relative magnitude of gene expression changes in 1 μM cisplatin-treated cells was generally more similar to the magnitude of changes in 25 μM transplatin treatments than in 1 μM transplatin treatments. This observation supports the final choice of isomer doses for comparison.

Apart from biological variables, another major experimental challenge relates to the intrinsic difficulties associated with the accurate measurement of gene expression -- a problem that is further enlarged by the number of genes on a microarray. A means of overcoming such technical variations is through correct experimental design and the implementation of analytical procedures that ensure the data is as free from systematic errors as possible ([@b45-cin-6-0315]; [@b175-cin-6-0315]). In the current study, these issues were primarily addressed within the preliminary investigations. Microarray experiments using slides with smaller gene-sets were employed to trial hybridisation and array-scanning techniques with fluorescent dyes. Also, these trials used cDNA samples derived from HeLa and K562 cancer cells, since these cell lines were well characterised and known to be stable. Subsequent experiments conducted with larger arrays compared control (DMF) and cisplatin-treated samples in order to ascertain whether a stable response to the anti-tumour drug could be detected. As expected, the magnitude of the differences in gene expression levels between control and treated samples was significantly lower than that observed between the profiles of the two different cell lines. However, the fact that a subset of genes was found to exhibit significantly different expression levels in response to drug treatment satisfied a major goal of this project, which was to establish a gene expression profile for cisplatin-treated human cells using microarray technology.

The ultimate aim of this work then became to develop a complete system for reliably determining differentially expressed genes in drug-treated cells. In future research, such a test system could then be used with confidence to investigate the cytotoxic potential of other compounds ([@b19-cin-6-0315]; [@b20-cin-6-0315]; [@b45-cin-6-0315]).

Oligonucleotide microarrays were used to investigate the transcriptional response of human fibroblasts to drug treatment. Through the use of refined normalisation procedures and rigorous statistical evaluation techniques, these experiments produced finite sets of genes that were classed as being differentially expressed in response to each of the three treatments examined. Additional cross-comparisons between different data sets led to the identification of a subset of genes that were differentially expressed between cisplatin and transplatin treatments.

The following sections briefly review and integrate the relevant literature relating to some of the more significant biological outcomes of the fibroblast microarray experiments. Particular emphasis is placed on the transcripts found to be differentially expressed between similarly toxic doses of cisplatin and transplatin. Since very rigorous and statistically robust methods for assessing differential gene expression were implemented in this part of the analysis, many of these transcripts are considered to be very good candidates for further investigation.

Transcriptional responses common to cisplatin and transplatin treatments
------------------------------------------------------------------------

The most important function of the one-sample B-statistic analyses was to identify genes with significantly different expression levels in control and drug-treated fibroblast samples. For all three treatments examined, results from the one-sample comparisons of microarray data clearly indicated that the cells exhibited a distinct transcriptional response to drug treatment (relative to control).

Differentially expressed transcripts were detected for each of the three treatments, forming separate transcription profiles for 1 μM cisplatin, 1 μM transplatin and 25 μM transplatin. Many of the differentially expressed transcripts were common to all three treatment profiles. However, considering the structural similarities between the two compounds and the relatively narrow dose range examined, this observation was not unexpected. A similar study by Burczynski and colleagues also describes a number of differentially expressed genes that are common to transcription profiles compiled for equitoxic doses of cisplatin and transplatin ([@b19-cin-6-0315]). Although it was not the purpose of this investigation to analyse these profiles in detail, it was interesting to note that some of the expression responses correlated well with observations from other DNA damage studies. For example, the interferon regulatory factors, IRF3 and IRF6, were both distinctly up-regulated in response to cisplatin and transplatin exposure in this study. The products of these genes are involved in a wide range of host defense mechanisms, and their activation by various environmental stresses, including DNA damage, has been well documented ([@b78-cin-6-0315]; [@b102-cin-6-0315]). In the case of down-regulated transcripts, glutathione peroxidase 1 (GPX1) demonstrated significantly reduced expression levels in the cisplatin and transplatin treatments examined here. Similarly, decreased glutathione peroxidase expression and activity levels have already been observed following cisplatin exposure in a range of biological systems ([@b67-cin-6-0315]; [@b76-cin-6-0315]; [@b116-cin-6-0315]; [@b131-cin-6-0315]). Overall, such correlations clearly support the results obtained in this study.

EASE software was used to determine gene categories that were significantly over-represented among the transcripts of each treatment profile (see [Table 3](#t3-cin-6-0315){ref-type="table"}). Similarities between these expression profiles meant that many of the over-represented gene categories were also common to the three treatment groups. A number of the commonly over-represented categories corresponded to functions that have been previously implicated in the cellular response to toxic insult. Some of these involved genes with established roles in biological processes such as transport, cell growth and/or maintenance, signal transduction, cell proliferation and regulation of cell cycle. Other significant groups, such as lipid metabolism (which was the most over-represented category among up-regulated genes, see [Table 3](#t3-cin-6-0315){ref-type="table"}), have only few or no former associations with the cellular response to DNA damage ([@b163-cin-6-0315]). Transcripts with roles in lipid metabolism included retinol dehydrogenase 16 (RODH-4), alkylglycerone phosphate synthase (AGPS) and apolipoprotein C-III (APOC3). Indeed, the complex series of events that results from drug-induced DNA damage involves multiple biological pathways, many of which are yet to be defined. Therefore, some of the significant genes identified here could prove to be novel regulators or mediators within the signal transduction pathways that are stimulated by DNA-adduct formation. Other transcripts may simply be part of the broader fibroblast response to toxic insult.

The next major goal of this investigation was to identify treatment-specific gene expression responses. While the microarray experiments that directly compared 1 μM cisplatin with 1 μM or 25 μM transplatin were originally designed to identify transcripts that were differentially expressed *between* treatments, one-sample B-statistic analyses failed to accurately reveal any such genes. It is most likely that systematic errors and biases in the microarray data significantly contributed to this outcome. However, as an alternative approach, two-sample B-statistic analyses were employed to facilitate the indirect comparison of expression profiles determined for the three 'control vs treatment' comparisons. Since these 'treatment' samples were all labelled with the same fluorescent dye (Cy3), this technique strongly reduced the likelihood of false positive results and dye-specific biases in the data. By implementing strict inclusion criteria and a robust definition for differential expression, the final outcome was a concise list of transcripts that were found to exhibit significantly different expression levels in cisplatin- and transplatin-treated fibroblasts.

Gene expression profiles unique to cisplatin and transplatin treatments
-----------------------------------------------------------------------

The two-sample comparison approach for inter-array data analysis readily identified transcripts that were differentially expressed between cisplatin and transplatin treatments. Altogether, 105 transcripts were found to be significantly more abundant in cisplatin treatments ([Tables 4](#t4-cin-6-0315){ref-type="table"}--[6](#t6-cin-6-0315){ref-type="table"}), while 64 transcripts were expressed to a greater extent in transplatin treatments ([Tables 7](#t7-cin-6-0315){ref-type="table"}--[9](#t9-cin-6-0315){ref-type="table"}). The application of gene ontology (GO) mapping and pathway analysis to this data illustrated the way in which such gene expression events could be placed in the context of the underlying pathways and processes affected. Among the 169 significant transcripts, EASE revealed a number of distinct and sometimes opposing biological themes. A particularly interesting result was 'negative regulation of cell proliferation', which was one of the more dominant themes associated with cisplatin treatments ([Table 10](#t10-cin-6-0315){ref-type="table"}). Genes assigned to this category included IL6, IL1B, IL8, TGFB1, GAS1, and ETS1. Other over-represented gene categories that reflected cisplatin's negative effects on cell growth were 'apoptosis', 'programmed cell death' and 'cell cycle arrest'. Together, these themes are consistent with cisplatin's effective cytotoxic mechanism.

In sharp contrast, EASE characterised transplatin's differential transcript profile with a significant proportion of genes involved in the 'positive regulation of cell proliferation' ([Table 11](#t11-cin-6-0315){ref-type="table"}). These included DTR, CUL3 and IRS2. Other subsets of genes abundant in transplatin treatments had established roles in a range of more general nucleic acid metabolism and processing functions. Among these, RNA/mRNA binding and splicing properties were common, and 'regulation of DNA-dependent transcription' was represented by at least eight genes. Broadly, these themes suggest that cellular activities following transplatin exposure are focused at the level of DNA/RNA interactions and various transcriptional processes. Together with the 'positive regulation of cell proliferation' gene group, this could partly indicate the early effort or ability of cells to overcome the interference of transplatin adducts and maintain normal cellular processes.

Other aspects of transplatin's differential transcript profile related to methods for circumventing the negative effects of platinum exposure. For example, several transcripts more abundant in transplatin treatments mapped to 'heavy metal sensitivity/resistance', 'metal ion homeostasis' and transport-related categories. This suggests that under the conditions employed here, some detoxification pathways may be more active in response to transplatin than to cisplatin. Some of these genes may play a role in processes that act to lower intracellular transplatin concentrations and thus help to prevent any drug-mediated interference with normal cell growth.

This interpretation would also be consistent with transplatin's status as the therapeutically inactive isomer.

In contrast, many of the dominating biological processes and molecular functions associated with cisplatin's differential expression profile were directly concerned with the immediate fate of a cell ([Table 10](#t10-cin-6-0315){ref-type="table"}). 'Regulation of cell proliferation', 'cell cycle arrest' and 'apoptosis' are prime examples of such crucial processes. Interestingly, these categories were not as significantly represented among the transcripts of transplatin's unique profile. However, since both adduct recognition and repair processes can differ significantly for damage induced by cisplatin and transplatin, this observation may reflect the early differential response of cells to the two isomers ([@b23-cin-6-0315]; [@b52-cin-6-0315]; [@b59-cin-6-0315]; [@b66-cin-6-0315]; [@b71-cin-6-0315]; [@b97-cin-6-0315][@b98-cin-6-0315]; [@b171-cin-6-0315]). Also, while cisplatin and transplatin have been shown to inhibit DNA synthesis in a similar manner ([@b15-cin-6-0315]; [@b23-cin-6-0315]; [@b53-cin-6-0315]; [@b59-cin-6-0315]; [@b98-cin-6-0315]; [@b132-cin-6-0315]), their differential effects on RNA transcription are also widely acknowledged ([@b17-cin-6-0315]; [@b26-cin-6-0315]; [@b36-cin-6-0315]; [@b98-cin-6-0315]; [@b111-cin-6-0315]; [@b177-cin-6-0315]). Thus, it seems likely that transcript profiles would also reflect such differences.

Overall, the results described here suggest that, even at low doses, cisplatin may elicit a more complex stress response in cells compared to transplatin. This might then imply that the need to determine the immediate fate of a cell is more urgent in response to cisplatin exposure. Supporting this notion was the abundance of transcripts pertaining to the immune system, communication and cell signalling processes in cisplatin treatments. In an attempt to further characterise the molecular events that may be associated with the anti-tumour activity of cisplatin, some of the genes found to be specifically regulated by cisplatin ([Tables 4](#t4-cin-6-0315){ref-type="table"} and [8](#t8-cin-6-0315){ref-type="table"}), were considered in more detail.

Inter-array two-sample B-statistic comparisons effectively revealed at least 169 transcripts that were differentially expressed between cisplatin and transplatin treatments. The incorporation of results from the one-sample 'control vs treatment' comparisons provided a means to clarify the origins of a subset of these differential responses. These subsets, presented in [Tables 4](#t4-cin-6-0315){ref-type="table"}, [5](#t5-cin-6-0315){ref-type="table"}, [7](#t7-cin-6-0315){ref-type="table"} and [8](#t8-cin-6-0315){ref-type="table"}, describe the more consistent and statistically significant transcriptional responses that were differentially elicited by cisplatin and transplatin in this study. A brief functional review of some of the better characterised genes that were specifically up- ([Table 4](#t4-cin-6-0315){ref-type="table"}) or down-regulated ([Table 8](#t8-cin-6-0315){ref-type="table"}) by cisplatin gave insight into some of the processes that may contribute towards the anti-tumour activity of this compound.

Genes specifically up-regulated in response to cisplatin
--------------------------------------------------------

The most common biological themes among the transcripts up-regulated by cisplatin involved cytokines, the regulation of cell proliferation, and other aspects of the cellular immune/defense response. Classed within each of these categories were the cytokines IL-1B, IL-6 and IL-8, which were all consistently up-regulated in response to cisplatin treatments. These molecules are important mediators of the inflammatory response and are also involved in a diverse range of cellular activities such as cell proliferation, differentiation, angiogenesis and apoptosis. Their ability to exert direct cytotoxic effects on tumour cells ([@b43-cin-6-0315]; [@b125-cin-6-0315]) or potentiate the effects of certain anti-tumour agents, has also been demonstrated ([@b13-cin-6-0315]). Therefore, the collective increase in cytokine transcripts observed in the cisplatin-specific expression profile was considered to be significant. Several studies have already demonstrated a significant rise in interleukin-1 levels after cisplatin treatments in cultured cells ([@b139-cin-6-0315]; [@b143-cin-6-0315]; [@b150-cin-6-0315]; [@b158-cin-6-0315]) and in patients undergoing chemotherapy ([@b8-cin-6-0315]). Furthermore, other groups have specifically reported that IL-1 enhances the sensitivity of tumour cells to cisplatin and that synergistic interactions between IL-1 and cisplatin may actually enhance p53-dependent apoptosis ([@b13-cin-6-0315]; [@b125-cin-6-0315]; [@b144-cin-6-0315]).

The behaviour of cytokines IL-6 and IL-8 has also been examined extensively, particularly in cancer patients ([@b8-cin-6-0315]; [@b16-cin-6-0315]; [@b28-cin-6-0315]). As for IL-1, an increased production of IL-6 and IL-8 in response to cisplatin has also been observed ([@b8-cin-6-0315]; [@b139-cin-6-0315]; [@b158-cin-6-0315]). In this study, the cisplatin-induced increase in IL-1B, IL-6 and IL-8 expression is thus consistent with previous findings and with the role of these cytokines as key biochemical modulators in a range of important biological functions.

Other elements of cisplatin's unique transcript profile relate to important signalling events that can affect DNA synthesis and cellular proliferation. For example, NMB, ITPR3 and PRKCBP1 are all implicated in the phosphoinositide cascade, which involves the activation of protein kinase C (PKC) and subsequent PKC-mediated effects. In this study, these three genes were specifically up-regulated in response to cisplatin exposure ([Table 4](#t4-cin-6-0315){ref-type="table"}). Neuromedin B (NMB) is a bombesin-like peptide found chiefly in the central nervous system and gastrointestinal tract ([@b100-cin-6-0315]; [@b101-cin-6-0315]; [@b114-cin-6-0315]). This peptide demonstrates autocrine and paracrine growth factor activity in some carcinomas ([@b84-cin-6-0315]; [@b105-cin-6-0315]; [@b107-cin-6-0315]; [@b121-cin-6-0315]), but in its role as a bifunctional regulator of cell growth, it can also significantly inhibit cell growth when at high levels ([@b31-cin-6-0315]). ITPR3 and PRKCBP1 have other roles in the PKC transduction pathway. ITPR3 is a second messenger receptor that acts as an intra-cellular calcium channel ([@b94-cin-6-0315]), while PRKCBP1 (protein kinase C binding protein 1) functions as an anchor for activated protein kinase C isoenzymes ([@b42-cin-6-0315]). At present, the precise role of the PKC transduction pathway in the cellular response to cisplatin is yet to be fully clarified ([@b47-cin-6-0315]; [@b56-cin-6-0315]). However, the cisplatin-enhanced expression of NMB, ITPR3 and PRKCBP1 in the current study may shed light on some of the key factors involved. Moreover, the absence of these expression events in the response to transplatin damage suggests a possible role for the phosphoinositide cascade in cisplatin's cytotoxic mechanism.

At least three transcripts among those specifically up-regulated by cisplatin had established or tentative growth suppressing properties: GAS1 (growth arrest specific 1), CDX1 (caudal type homeobox transcription factor 1) and AIM1 (absent in melanoma 1). GAS1 is an integral plasma membrane protein directly involved in the negative regulation of cell proliferation and, in some cases, apoptosis ([@b30-cin-6-0315]; [@b37-cin-6-0315]; [@b172-cin-6-0315]). CDX1 encodes an intestine-specific transcription factor that demonstrates both pro-oncogenic functions and growth-inhibitory effects ([@b32-cin-6-0315]; [@b92-cin-6-0315]). AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is a putative suppressor of human malignant melanoma and is associated with the control and experimental reversal of tumourigenicity ([@b126-cin-6-0315]). To date, GAS1, CDX1 and AIM1 have not been implicated in the response of cells to cisplatin damage.

In contrast, cisplatin-induced transcripts that have been shown to influence cell growth in a positive manner include CDC25B, G0S2 and AGER. CDC25B (cell division cycle 25B) and G0S2 (putative lymphocyte G0/G1 switch gene) both exert their most prominent effects through the regulation of the cell cycle. CDC25B and other CDC25 genes encode protein threonine/tyrosine phosphatases that drive cell cycle progression through the activation of cyclin dependent kinases. With obvious growth-promoting properties, CDC25B over-expression has been demonstrated in a number of cancers including head, neck, gastric, ovarian, esophageal and prostate tumours, as well as non Hodgkin's lymphoma ([@b18-cin-6-0315]; [@b46-cin-6-0315]; [@b60-cin-6-0315]; [@b80-cin-6-0315]; [@b83-cin-6-0315]; [@b104-cin-6-0315]; [@b118-cin-6-0315]). While the precise function of G0S2 is yet to be established, its major role in cell cycle regulation is believed to involve the switch of lymphocytes from G0 to G1 phases ([@b27-cin-6-0315]; [@b130-cin-6-0315]). AGER (advanced glycosylation end product-specific receptor), or RAGE, is generally a tumour-associated antigen and has been shown to stimulate cell proliferation and survival ([@b2-cin-6-0315]; [@b7-cin-6-0315]; [@b34-cin-6-0315]; [@b65-cin-6-0315]). Also, at least one study has implicated AGER in the up-regulation of the pro-inflammatory cytokine IL-6 ([@b33-cin-6-0315]), which was also induced in the current study.

Genes specifically down-regulated in response to cisplatin
----------------------------------------------------------

Within this study, many of the transcripts found to be specifically down-regulated in response to cisplatin ([Table 8](#t8-cin-6-0315){ref-type="table"}) appeared to be more consistently associated with tumour-promoting or growth-stimulating effects. This finding is significant because the relative inhibition of such effects via decreased gene expression could contribute to the efficient anti-tumour mechanism of cisplatin. Among the down-regulated transcripts, genes that have been specifically linked with the potential for promoting growth and/or proliferation include: ephrin-B2 (EFNB2), angiopoietin-like 4 (ANG-PTL4), diphtheria toxin receptor (DTR) and splicing factor proline/glutamine rich (SFPQ). Such associations are outlined briefly, below.

The ephrin-B2 gene encodes a member of the ephrin (EPH) family which, along with the EPH-related receptors, comprise a large subfamily of receptor protein-tyrosine kinases ([@b14-cin-6-0315]). Members have been most strongly been implicated in mediating developmental events, particularly in the central nervous system ([@b153-cin-6-0315]) and in erythropoiesis ([@b148-cin-6-0315]). EFNB2 expression has also been associated with cellular proliferation ([@b11-cin-6-0315]; [@b147-cin-6-0315]), cell migration ([@b147-cin-6-0315]), angiogenesis ([@b119-cin-6-0315]) and the progression of a wide range of human cancers, including malignant melanoma ([@b163-cin-6-0315]), small cell lung carcinoma ([@b155-cin-6-0315]), osteosarcoma ([@b160-cin-6-0315]), endometrial cancer ([@b152-cin-6-0315]), colon/colorectal carcinoma ([@b91-cin-6-0315]) and breast cancer ([@b119-cin-6-0315]). In fact, the capacity of the EFNB2 ligand to increase the potential for growth, tumourigenicity and metastasis in many of these tumour cells is becoming increasingly apparent ([@b119-cin-6-0315]; [@b152-cin-6-0315]; [@b163-cin-6-0315]).

The ANGPTL4 gene encodes an angiopoietin-like secreted glycoprotein ([@b77-cin-6-0315]; [@b169-cin-6-0315]). It is one of the targets of the nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARgamma), and has proposed roles in adipose differentiation, lipid metabolism, glucose homeostasis and angiogenesis ([@b22-cin-6-0315]; [@b75-cin-6-0315]; [@b86-cin-6-0315]; [@b87-cin-6-0315]; [@b137-cin-6-0315]; [@b169-cin-6-0315]; [@b176-cin-6-0315]). Like EFNB2, ANGPTL4 has also been associated with the development of a range of cancers, including colorectal cancer, renal cell carcinoma, bladder tumours and gastric cancer ([@b72-cin-6-0315]; [@b85-cin-6-0315]; [@b86-cin-6-0315]; [@b170-cin-6-0315]).

DTR, also known as the heparin-binding EGF-like growth factor (HB-EGF), encodes a transmembrane protein that interacts with membrane protein DRAP27/CD9 to form the functional diphtheria toxin receptor ([@b40-cin-6-0315]; [@b57-cin-6-0315]; [@b62-cin-6-0315]; [@b70-cin-6-0315]). In keeping with the growth-promoting characteristics of other down-regulated transcripts in this study, DTR demonstrates growth factor activity and mitogenic activity ([@b61-cin-6-0315]; [@b62-cin-6-0315]). The capacity of the diphtheria toxin receptor to stimulate cell migration and proliferation has also been documented ([@b61-cin-6-0315]; [@b69-cin-6-0315]; [@b81-cin-6-0315]), as has its contribution to the tumourigenesis of gastric epithelial cell cancers ([@b108-cin-6-0315]; [@b164-cin-6-0315]).

SFPQ (splicing factor proline/glutamine rich) is a novel and essential pre-mRNA splicing factor ([@b123-cin-6-0315]). It has been implicated in both early and late steps of pre-mRNA splicing and is required in spliceosome formation ([@b123-cin-6-0315]). With a number of roles in various nuclear processes, SFPQ has also been linked with virally-mediated steroidogenesis and oncogenesis ([@b145-cin-6-0315]). Another positive association with cellular proliferation is the DNA-pairing activity exhibited by this protein, which has been directly implicated in the reestablishment of stalled replication forks ([@b3-cin-6-0315]).

Among the remaining transcripts in this study with reduced expression levels in response to cisplatin exposure, the metallothionein-1L (MT1L) and transferrin receptor (TFRC) genes have been most thoroughly studied and characterised. Although not directly associated with the promotion of cell growth, MT1L and TFRC respectively play major roles in metal detoxification and iron metabolism, both of which are essential cellular processes. Furthermore, the relative effect of cisplatin treatment on MT1L and TFRC has already been addressed in a number of studies, as discussed below.

Metallothioneins are intracellular metal-binding proteins that are generally found to confer drug resistance when induced in tumour tissues. Metallothionein-mediated cisplatin resistance, for instance, is well documented ([@b9-cin-6-0315]; [@b10-cin-6-0315]; [@b35-cin-6-0315]; [@b74-cin-6-0315]; [@b135-cin-6-0315]; [@b149-cin-6-0315]; [@b168-cin-6-0315]). Although cisplatin has also been found to induce metallothionein expression in tumour cells ([@b12-cin-6-0315]; [@b39-cin-6-0315]; [@b54-cin-6-0315]; [@b82-cin-6-0315]; [@b96-cin-6-0315]; [@b141-cin-6-0315]; [@b174-cin-6-0315]), induction appears to be dependent on the protein isoform and the drug-resistant status of the cells ([@b79-cin-6-0315]; [@b112-cin-6-0315]). Furthermore, metallothionein has also been shown to exhibit a biphasic transcriptional response to DNA damage in which early expression levels are largely depressed ([@b51-cin-6-0315]). In considering these observations, it is thus possible that reduced metallothionein expression could contribute to early drug-induced anti-proliferative effects by lessening the chemo-protection that is usually afforded by increased metallothionein levels. In further support of the findings reported in this thesis, comparative studies with cisplatin and transplatin have shown that the inactive isomer interacts at a significantly faster rate with metallothionein, and does not appear to induce its biosynthesis ([@b39-cin-6-0315]; [@b54-cin-6-0315]; [@b173-cin-6-0315]; [@b174-cin-6-0315]).

As introduced above, the transferrin receptor gene, TFRC, encodes a glycoprotein with an essential role in iron metabolism ([@b120-cin-6-0315]; [@b138-cin-6-0315]). Several interesting relationships between cisplatin and TFRC have also been revealed. Firstly, the ability of cisplatin to bind transferrin is well established, and there is evidence that the cisplatin-transferrin complex can be transported into cells via the transferrin receptor ([@b4-cin-6-0315]; [@b48-cin-6-0315]; [@b49-cin-6-0315]; [@b58-cin-6-0315]; [@b151-cin-6-0315]). In another study, cisplatin-induced transferrin modulation was found to be accompanied by severe spermatogenic damage in rat testes ([@b115-cin-6-0315]). This observation may be significant because it has the potential to provide insight into the enhanced sensitivity of testicular carcinomas to cisplatin-based therapies.

Various studies have also documented the reduced expression of TFRC mRNA after cisplatin treatment ([@b95-cin-6-0315]; [@b122-cin-6-0315]; [@b156-cin-6-0315]), an observation that is consistent with the findings reported in the current study. Moreover, [@b95-cin-6-0315] observed that this effect correlated well with low TFRC protein expression and the inhibition of DNA synthesis and cellular proliferation. Conversely, a number of studies have reported a distinct correlation between higher levels of TFRC expression and increased cellular proliferation in cancer cells ([@b103-cin-6-0315]; [@b106-cin-6-0315]; [@b146-cin-6-0315]). Together, these findings suggest a more defined role for TFRC in promoting cellular growth and proliferation -- again, a common theme among the genes down-modulated by cisplatin in this study. Overall, the connection between TFRC and cisplatin damage is potentially an interesting one, and certainly worthy of further study.

Conclusion
==========

In conclusion, the current study has utilised microarrays to identify a number of genes that are differentially expressed in human cells in response to cisplatin and transplatin treatments. However, the functional interpretation of transcriptional events revealed by microarray analysis still presents a major challenge. Researching the known properties and functions of such genes is indeed a small but important step towards understanding their biological relevance in the experimental context of interest. In the present study, such investigations provided insight into several gene expression responses that are uniquely elicited by cisplatin with respect to its clinically ineffective isomer, transplatin. This data has indicted a number of genes that would be strong candidates for further gene function analysis that can mimic the effect of cisplatin at the gene expression level.
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![The chemical structures of cisplatin and transplatin\
The main focus of this study is the mechanism of action of the DNA-damaging anti-cancer drug, cisplatin. Although structurally similar, cisplatin's isomer, transplatin, lacks the anti-tumour activity exhibited by](cin-6-0315f1){#f1-cin-6-0315}

![AlamarBlueTM Cytotoxicity Assay: Human fibroblasts treated with cisplatin and transplatin\
Graphs indicate the % Cell Survival at (**a**) 8 and (**b**) 24 hours for 0.1--100μM Cisplatin and Transplatin. The data points shown are for drug concentrations of 0.1, 0.3, 1.0, 10, 25 and 100 μM, and have been averaged across three replicate values. Error bars represent the standard error of the mean. (Note: Scale of x-axis is in logarithmic format).](cin-6-0315f2){#f2-cin-6-0315}

![MA-plot of normalised data for DMF (control) versus 1 μM cisplatin treatment comparison\
M (Log~2~(expression ratio)) and A (relative intensity) values were averaged across 4 replicate microarrays. M values greater than zero indicate transcripts which responded to cisplatin with decreased expression levels, while M values less than zero indicate transcripts with increased expression levels after cisplatin treatment.](cin-6-0315f3){#f3-cin-6-0315}

![Overview of the two-sample comparison B-statistic analysis\
This approach facilitated the simultaneous comparison of data from 'DMF (control) vs 1 μM cisplatin' and 'DMF (control) vs 25 μM transplatin' microarray comparisons. Through the *inter*-array comparison of treatments labeled with the same dye, B-statistics were used to detect subtle differences in the expression responses to cisplatin and transplatin without the interference of dye biases. During this analysis, 105 transcripts were found to be significantly more abundant in the 1 μM cisplatin treatments while 64 transcripts were more abundant in the 25 μM transplatin treatments. The origin or cause of these differential expression events was then clarified by cross-comparing two-sample comparison results with those of the one-sample comparisons. Positive correlations then allowed significant transcripts to be classified as being actively up-regulated by cisplatin, down-regulated by transplatin, unregulated by transplatin or down-regulated by cisplatin. Other significant transcripts could not be classified into one of the four categories above, due to the absence of corresponding one-sample comparison data.](cin-6-0315f4){#f4-cin-6-0315}

###### The number of differentially expressed transcripts identified within each key treatment comparison

For each control vs treatment comparison, significant responses are divided into up- and down-regulated gene subsets. For two-sample indirect treatment comparisons, differentially expressed transcripts were identified as being either more abundant in 1μM cisplatin treatments or 25μM transplatin treatments. The average and highest expression fold-changes within each significant subset are also indicated.

                                                  Treatment comparison                                  Significant gene subset                     Number of significant genes (B 3 0)          Average fold-change            Highest Fold-change (gene name)
  ----------------------------------------------- ----------------------------------------------------- ------------------------------------------- -------------------------------------------- ------------------------------ -------------------------------------
  One-sample                                      Control (DMF) vs 1μM Cisplatin                        Transcripts up-regulated by 1μM Cisplatin   ↑ 1227                                       2.81                           **19.27** (REM protein, REM)
  Transcripts down-regulated by 1μM cisplatin     ↓ 316                                                 2.02                                        **3.63** (cDNA DKFZp564D2071)                                               
  Control (DMF) vs 1μM Transplatin                Transcripts up-regulated by 1μM transplatin           ↑ 1293                                      2.78                                         **16.51** (REM protein, REM)   
  Transcripts down-regulated by 1μM transplatin   ↓ 352                                                 1.95                                        **3.28** (MHC class II DPw3-alpha-1 chain)                                  
  Control (DMF) vs 25μM Transplatin               Transcripts up-regulated by25μM transplatin           ↑ 1319                                      2.83                                         **20.37** (REM protein, REM)   
  Transcripts down-regulated by25μM transplatin   ↓ 561                                                 1.91                                        **3.63** (cDNA DKFZp564D2071)                                               
  Two-sample                                      Control (DMF) vs 1μM Cisplatin and 25μM Transplatin   Transcripts more abundant in1μM cisplatin   105                                          1.71                           **3.29** (interleukin 1-beta (IL1B)
  Transcripts more abundant in 25μM transplatin   64                                                    1.65                                        **2.36** (cDNA FLJ12109 fis)                                                

###### One-Sample Comparison B-statistic Analysis: The first 20 known genes with significantly (a) higher and (b) lower expression levels in cells treated with 1 μM cisplatin

Transcripts are ranked in order of evidence for differential expression, according to one-sample comparison B-statistics and corresponding M and P-values. For each transcript with at least two data points, the average fold-change was calculated from the replicate values shown. Overall, 1245 transcripts were found to be significantly up-regulated in response to 1 μM cisplatin, while 352 were significantly down-regulated following treatment. Transcripts highlighted in yellow demonstrated the same expression response in transplatin treated cells.

  Accession \#                                                       Full gene name                                                                                                                     Average fold-Change   B-statistic   M        P-value
  ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------- --------------------- ------------- -------- ---------
  **(a)** Transcripts Up-regulated in response to 1 μM Cisplatin                                                                                                                                                                                     
  U12767                                                             Human mitogen induced nuclear orphan receptor (MINOR) mRNA                                                                         **8.27**              **8.243**     −3.040   0.00026
  M26747                                                             Human c-erbA mRNA, complete cds                                                                                                    **9.70**              **8.081**     −3.265   0.00026
  X59845                                                             Human mRNA for a Krab domain upstream to Kox 8 gene                                                                                **5.50**              **8.045**     −2.503   0.00026
  D17259                                                             Human HepG2 3′-region MboI mRNA, clone hmd5d07m3                                                                                   **3.18**              **8.025**     −1.666   0.00026
  AF223389                                                           PCGEM1 gene, non-coding mRNA                                                                                                       **7.44**              **7.965**     −2.888   0.00026
  NM_006515                                                          SET domain and mariner transposase fusion gene (SETMAR) mRNA                                                                       **7.18**              **7.716**     2.848    0.00026
  NM_006666                                                          RuvB (E coli homolog)-like 2 (RUVBL2) mRNA                                                                                         **5.53**              **7.690**     −2.504   0.00026
  NM_003708                                                          microsomal NAD+-dependent retinol dehydrogenase 4 (RODH-4) MRNA                                                                    **6.84**              **7.488**     −2.764   0.00026
  NM_004010                                                          dystrophin (muscular dystrophy, Duchenne and Becker types), (DMD), transcript variant Dp427p2, mRNA                                **4.83**              **7.354**     −2.270   0.00028
  NM_003743                                                          nuclear receptor coactivator 1 (NCOA1), mRNA                                                                                       **6.23**              **7.326**     −2.630   0.00028
  NM_005677                                                          single strand of homotrimeric collagen-like tail subunit of asymmetric acetylcholinesterase (COLQ) mRNA                            **3.87**              **7.235**     1.951    0.00029
  NM_005558                                                          ladinin 1 (LAD1) mRNA                                                                                                              **5.01**              **7.161**     −2.322   0.00029
  NM_016063                                                          CGI-130 protein (LOC51020), mRNA                                                                                                   **4.58**              **7.142**     −2.194   0.00029
  NM_001571                                                          interferon regulatory factor 3 (IRF3) mRNA                                                                                         **5.61**              **7.112**     −2.405   0.00030
  AF298152                                                           mRNA polymerase III transcription initiation factor B″ short mRNA                                                                  **4.46**              **7.047**     −2.155   0.00030
  L48516                                                             paraoxonase 3 (PON3) mRNA, 3′-end of cds                                                                                           **4.85**              **6.840**     −2.273   0.00036
  AF274863                                                           Secretory pathway component Sec31B-1 mRNA, alternatively Spliced                                                                   **2.47**              **6.754**     −1.301   0.00039
  AF205632                                                           zinc finger protein 106 (ZFP106) mRNA, complete cds                                                                                **5.75**              **6.750**     −2.510   0.00039
  NM_012332                                                          Mitochondrial Acyl-CoA Thioesterase (MT-ACT48), mRNA                                                                               **4.17**              **6.667**     −2.058   0.00039
  NM_004375                                                          COX11 (yeast) homolog, cytochrome c oxidase assembly protein, MRNA                                                                 **3.24**              **6.591**     −1.685   0.00041
  **(b)** Transcripts Down-regulated in Response to 1 μM Cisplatin                                                                                                                                                                                   
  NM_002450                                                          metallothionein 1L (MT1L) mRNA                                                                                                     2.20                  5.218         1.133    0.00063
  NM_003539                                                          H4 histone family, member B (H4FB) mRNA                                                                                            3.56                  4.002         1.758    0.00100
  NM_002307                                                          lectin, galactoside-binding, soluble, 7 (galectin 7) (LGALS7) mRNA                                                                 2.31                  3.707         1.206    0.00108
  M87941                                                             Human carcinoma cell-derived Alu RNA transcript, clone ALU20                                                                       2.48                  3.468         1.301    0.00122
  NM_015885                                                          PCF11p homolog (LOC51585), mRNA                                                                                                    1.91                  3.435         0.925    0.00110
  AF040247                                                           erythroid differentiation-related factor 1 mRNA, partial cds                                                                       3.07                  3.379         1.573    0.00130
  M92273                                                             Human dihydropyridine-sensitive calcium channel HFCC, 3′-end intron 4                                                              2.30                  3.272         1.200    0.00133
  NM_005066                                                          splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated) (SFPQ) mRNA                               1.70                  3.191         0.768    0.00123
  U62823                                                             Human small nuclear RNA U6atac, partial sequence                                                                                   1.77                  3.029         0.826    0.00133
  Y10206                                                             H.sapiens mRNA for CD64 protein                                                                                                    3.37                  2.943         1.791    0.00158
  NM_012348                                                          olfactory receptor 89 (OLFR89), mRNA                                                                                               2.28                  2.902         1.178    0.00161
  X96644                                                             H.sapiens mRNA for U45a small nuclear RNA                                                                                          2.12                  2.791         1.083    0.00166
  AY010111                                                           cadherin-23 (CDH23) mRNA, partial cds                                                                                              2.17                  2.513         1.113    0.00187
  U50539                                                             Human BRCA2 region, mRNA sequence GT605                                                                                            2.21                  2.470         1.138    0.00192
  NM_005553                                                          keratin, cuticle, ultrahigh sulphur 1 (KRN1), mRNA HERV-H homolog/ya88a12s.1 homolog (A_T-rich region, putative retrotransposon)   2.20                  2.423         1.132    0.00195
  S83307                                                             \[human, phytohemaglutinin-stimulated peripheral T-cells, mRNA \]                                                                  2.11                  2.389         1.091    0.00205
  Y16701                                                             mRNA from HIV associated non-Hodgkin's lymphoma (clone hl1--72)                                                                    2.06                  2.387         1.039    0.00199
  AF124819                                                           T84 colon carcinoma cell IL-1beta regulated HSCC1 mRNA                                                                             2.29                  2.374         1.166    0.00205
  NM_014387                                                          linker for activation of T cells (LAT), mRNA                                                                                       1.78                  2.323         0.829    0.00190
  NM_005110                                                          Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) mRNA                                                                         1.70                  2.252         0.767    0.00188

###### One-Sample Comparison B-statistic Analysis: The first 20 most significantly over-represented gene categories among transcripts with significantly (a) higher and (b) lower expression levels in cells treated with 1 μM cisplatin

The number of transcripts in each gene category (List Hits) is also presented as a percentage of all the transcripts belonging to that category that were actually present on the microarray (Population Hits). Gene categories denoted with an asterisk were also significantly over-represented among transcripts demonstrating the same expression response in transplatin treated cells.

  Rank                                                                            GO system            Gene category                                              List hits   Population hits   \% Population hits   EASE score
  ------------------------------------------------------------------------------- -------------------- ---------------------------------------------------------- ----------- ----------------- -------------------- ----------------
  **(a)** Gene categories over-represented among **up-regulated** transcripts                                                                                                                                        
  1                                                                               Biological Process   lipid metabolism \*                                        **100**     474               21                   1.79 × 10^−19^
  2                                                                               Biological Process   transport \*                                               **210**     1646              13                   8.23 × 10^−13^
  3                                                                               Biological Process   membrane lipid metabolism \*                               **27**      93                29                   1.05 × 10^−08^
  4                                                                               Biological Process   phospholipid metabolism \*                                 **21**      59                36                   1.44 × 10^−08^
  5                                                                               Biological Process   lipid biosynthesis \*                                      **36**      164               22                   6.93 × 10^−08^
  6                                                                               Molecular Function   transporter activity \*                                    **178**     1542              12                   1.29 × 10^−07^
  7                                                                               Molecular Function   porter activity \*                                         **37**      184               20                   3.77 × 10^−07^
  8                                                                               Molecular Function   electrochemical potential-driven transporter activity \*   **37**      185               20                   4.33 × 10^−07^
  9                                                                               Biological Process   phospholipid biosynthesis \*                               **14**      33                42                   6.86 × 10^−07^
  10                                                                              Molecular Function   dynein ATPase activity \*                                  **9**       14                64                   3.15 × 10^−06^
  11                                                                              Molecular Function   carrier activity \*                                        **60**      406               15                   4.40 × 10^−06^
  12                                                                              Biological Process   lipid transport \*                                         **16**      54                30                   1.50 × 10^−05^
  13                                                                              Cellular Component   intermediate filament cytoskeleton \*                      **18**      69                26                   1.81 × 10^−05^
  14                                                                              Biological Process   membrane lipid biosynthesis \*                             **14**      43                33                   2.05 × 10^−05^
  15                                                                              Molecular Function   motor activity \*                                          **24**      112               21                   2.10 × 10^−05^
  16                                                                              Molecular Function   microtubule motor activity \*                              **14**      44                32                   2.51 × 10^−05^
  17                                                                              Molecular Function   lipid transporter activity \*                              **16**      58                28                   3.52 × 10^−05^
  18                                                                              Biological Process   alcohol metabolism \*                                      **35**      211               17                   0.00007
  19                                                                              Biological Process   endocytosis \*                                             **22**      107               21                   0.00010
  20                                                                              Biological Process   steroid metabolism \*                                      **22**      109               20                   0.00014
  **(b)** Gene categories over-represented among **down-regulated** transcripts                                                                                                                                      
  1                                                                               Molecular Function   signal transducer activity \*                              **32**      1901              1.7                  0.0006
  2                                                                               Molecular Function   sugar binding \*                                           **6**       99                6.1                  0.0021
  3                                                                               Molecular Function   receptor activity \*                                       **21**      1163              1.8                  0.0037
  4                                                                               Biological Process   cell surface receptor linked signal transduction \*        **19**      968               2.0                  0.0047
  5                                                                               Molecular Function   transmembrane receptor activity \*                         **14**      756               1.9                  0.0195
  6                                                                               Biological Process   response to abiotic stimulus \*                            **11**      494               2.2                  0.0202
  7                                                                               Biological Process   development \*                                             **25**      1646              1.5                  0.0215
  8                                                                               Biological Process   cell communication \*                                      **37**      2744              1.3                  0.0216
  9                                                                               Cellular Component   membrane \*                                                **48**      4039              1.2                  0.0321
  10                                                                              Biological Process   neuropeptide signaling pathway \*                          **4**       87                4.6                  0.0512
  11                                                                              Biological Process   perception of abiotic stimulus \*                          **7**       280               2.5                  0.0527
  12                                                                              Biological Process   sensory perception \*                                      **7**       292               2.4                  0.0621
  13                                                                              Biological Process   cell-cell adhesion \*                                      **5**       166               3.0                  0.0757
  14                                                                              Biological Process   perception of external stimulus                            **7**       308               2.3                  0.0761
  15                                                                              Biological Process   neurogenesis \*                                            **8**       392               2.0                  0.0831
  16                                                                              Biological Process   endocytosis \*                                             **4**       107               3.7                  0.0838
  17                                                                              Biological Process   signal transduction \*                                     **28**      2167              1.3                  0.0839
  18                                                                              Biological Process   G-protein coupled receptor protein signaling pathway \*    **10**      564               1.8                  0.0923
  19                                                                              Biological Process   perception of chemical substance                           **3**       54                5.6                  0.0949
  20                                                                              Cellular Component   nucleoplasm                                                **12**      787               1.5                  0.1132

###### Two-sample comparison B-statistic analysis: transcripts significantly up-regulated in 1 μM cisplatin treatments (relative to both DMF (control) and 25 μM transplatin treatments)

Transcripts are ranked in order of evidence for differential expression according to one-sample comparison B-statistics and corresponding P-values.

  Accession \#   Gene symbol   Full gene name                                         FOLD-change   B-statistic   P-value   Representative gene category                EASE score
  -------------- ------------- ------------------------------------------------------ ------------- ------------- --------- ------------------------------------------- ------------
  M15330         IL1B          interleukin 1, beta                                    **3.29**      7.88          0.0002    negative regulation of cell proliferation   0.0023
  M21551         NMB           neuromedin B                                           **2.43**      7.83          0.0002    cell communication                          0.0279
  AK022077       BAALC         brain and acute leukemia, cytoplasmic                  **2.55**      4.96          0.0040                                                
  NM_015714      G0S2          putative lymphocyte G0/G1 switch gene                  **2.75**      4.72          0.0047    regulation of cell cycle                    0.0001
  AK027167       FLJ23514      hypothetical protein FLJ23514                          **1.79**      4.41          0.0055    protein metabolism                          0.8321
  AB036432       AGER          advanced glycosylation end product-specific receptor   **1.86**      4.14          0.0058    response to pest/pathogen/parasite          0.0021
  NM_005512      GARP          glycoprotein A repetitions predominant                 **2.79**      3.75          0.0077    response to external stimulus               0.0075
  M14584         IL6           interleukin 6 (interferon, beta 2)                     **1.70**      3.53          0.0089    positive regulation of cell proliferation   0.1881
  NM_002224      ITPR3         inositol 1,4,5-triphosphate receptor, type 3           **1.88**      3.12          0.0120    signal transducer activity                  0.2901
  AL157504                     unknown                                                **2.20**      2.68          0.0167                                                
  AK021624       C5orf13       chromosome 5 open reading frame 13                     **2.13**      2.62          0.0170                                                
  AK026341       FLJ22688      hypothetical protein FLJ22688                          **2.25**      2.54          0.0180    cell growth and/or maintenance              0.2968
  AK024330       PAPPA         pregnancy-associated plasma protein A                  **1.71**      2.29          0.0206    zinc ion binding                            0.0667
  NM_002048      GAS1          growth arrest-specific 1                               **2.01**      2.25          0.0206    negative regulation of cell proliferation   0.0023
  NM_014400      C4.4A         GPI-anchored metastasis-associated protein homolog     **1.67**      2.03          0.0217    cell communication                          0.0279
  NM_018006      FLJ10140      hypothetical protein FLJ10140                          **1.87**      1.82          0.0252    tRNA metabolism                             0.5373
  NM_019885      P450RAI-2     cytochrome P450 retinoid metabolizing protein          **1.70**      1.58          0.0290    oxidoreductase activity                     0.8690
  NM_004358      CDC25B        cell division cycle 25B                                **1.76**      1.57          0.0290    regulation of cell cycle                    0.0001
  AK022207       MLPH          melanophilin                                           **1.67**      1.33          0.0333                                                
  U83115         AIM1          absent in melanoma1                                    **1.69**      1.29          0.0339    cell adhesion                               0.3235
  NM_015524      C6orf4        chromosome 6 open reading frame 4                      **1.54**      1.03          0.0370    cell communication                          0.0279
  NM_000022      ADA           adenosine deaminase                                    **1.42**      0.93          0.0382    response to pest/pathogen/parasite          0.0021
  AF085920                     unknown                                                **1.53**      0.60          0.0460                                                
  M17017         IL8           interleukin 8                                          **1.64**      0.56          0.0460    negative regulation of cell proliferation   0.0023
  NM_006332      IFI30         interferon, gamma-inducible protein 30                 **1.56**      0.52          0.0469    immune response                             0.0038
  NM_001804      CDX1          caudal type homeo box transcription factor 1           **1.66**      0.28          0.0564    morphogenesis                               0.0427
  AF233453       PRKCBP1       protein kinase C binding protein 1                     **1.62**      0.01          0.0664    transcription\\, DNA-dependent              0.9772

###### Two-sample comparison B-statistic analysis: transcripts significantly down-regulated in 25 μM transplatin treatments (relative to both DMF (control) and 1 μM cisplatin treatments)

Transcripts are ranked in order of evidence for differential expression according to one-sample comparison B-statistics and corresponding P-values.

  Accession \#   Gene symbol   Full gene name                                                                                                     FOLD-change   B-statistic   P-value   Representative gene category                          EASE score
  -------------- ------------- ------------------------------------------------------------------------------------------------------------------ ------------- ------------- --------- ----------------------------------------------------- ------------
  NM_007286      SYNPO         synaptopodin                                                                                                       **2.13**      4.50          0.0055    hydrolase activity                                    0.7902
  NM_003028      SHB           SHB (Src homology 2 domain containing) adaptor protein B                                                           **1.87**      4.40          0.0055    cell communication                                    0.0279
  NM_005438      FOSL1         FOS-like antigen 1                                                                                                 **2.06**      4.33          0.0056    positive regulation of cell proliferation             0.1881
  AL359568                     unknown                                                                                                            **1.86**      4.25          0.0057                                                          
  NM_005940      MMP11         matrix metalloproteinase 11 (stromelysin 3)                                                                        **1.86**      4.14          0.0058    zinc ion binding                                      0.0667
  NM_000362      TIMP3         tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)                              **2.10**      3.63          0.0082    response to external stimulus                         0.0075
  NM_015719      COL5A3        collagen, type V, alpha 3                                                                                          **1.94**      3.36          0.0102    cell adhesion                                         0.3235
  AF075060                     unknown                                                                                                            **1.56**      3.35          0.0102                                                          
  NM_018579      MSCP          mitochondrial solute carrier protein                                                                               **1.65**      3.27          0.0109    cell growth and/or maintenance                        0.2968
  AK024488       FLJ21438      hypothetical protein FLJ21438                                                                                      **1.79**      2.96          0.0139                                                          
  NM_002997      SDC1          syndecan 1                                                                                                         **1.63**      2.51          0.0182    cytoskeletal protein binding                          0.5656
  NM_003040      SLC4A2        solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1)                    **1.58**      2.48          0.0185    cell growth and/or maintenance                        0.2968
  M16006         SERPINE1      serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1       **1.82**      2.16          0.0208    enzyme regulator activity                             0.1463
  U79458                       unknown                                                                                                            **1.52**      2.14          0.0208                                                          
  U90908         RhoGAP2       Rho GTPase activating protein 2                                                                                    **1.51**      2.07          0.0214    tRNA metabolism                                       0.5373
  AB033050       RAI17         retinoic acid induced 17                                                                                           **1.74**      2.04          0.0216    zinc ion binding                                      0.0667
  AK001058                     unknown                                                                                                            **1.54**      1.52          0.0292                                                          
  AF086287                     unknown                                                                                                            **1.69**      1.49          0.0292                                                          
  NM_007182      RASSF1        Ras association (RalGDS/AF-6) domain family 1                                                                      **1.42**      1.39          0.0318    cell communication                                    0.0279
  NM_006288      THY1          Thy-1 cell surface antigen                                                                                         **1.62**      1.27          0.0339    cell growth and/or maintenance                        0.2968
  AK026108       SEMA4B        sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B   **1.64**      1.27          0.0339    neurogenesis                                          0.7846
  NM_002103      GYS1          glycogen synthase 1 (muscle)                                                                                       **1.56**      1.20          0.0353    energy derivation by oxidation of organic compounds   0.5979
  AL390147       FAM20C        family with sequence similarity 20, member C                                                                       **1.52**      1.20          0.0353                                                          
  NM_003565      ULK1          unc-51-like kinase 1 (C. elegans)                                                                                  **1.48**      1.13          0.0353    kinase activity                                       0.5026
  AF238083       SPHK1         sphingosine kinase 1                                                                                               **1.50**      1.01          0.0370    regulation of cell cycle                              0.0001
  NM_006497      HIC1          hypermethylated in cancer 1                                                                                        **1.59**      0.91          0.0383    negative regulation of cell cycle                     0.0876
  NM_014623      MEA           male-enhanced antigen                                                                                              **1.57**      0.87          0.0395    gonad development                                     0.1233
  NM_015923      SLC7A5        solute carrier family 7 (cationic amino acid transporter, y+ system), member 5                                     **1.38**      0.85          0.0396    cell growth and/or maintenance                        0.2968
  AB007871       SRGAP2        SLIT-ROBO Rho GTPase activating protein 2                                                                          **1.4**       0.68          0.0432    cell communication                                    0.0279
  NM_003289      TPM2          tropomyosin 2 (beta)                                                                                               **1.42**      0.67          0.0432    cell motility                                         0.0688
  NM_005178      BCL3          B-cell CLL/lymphoma 3                                                                                              **1.45**      0.47          0.0486    regulation of cell cycle                              0.0001
  NM_005730      CTDSP2        CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2                                **1.72**      0.41          0.0507    oncogenesis                                           0.3266
  NM_006373      VAT1          vesicle amine transport protein 1 homolog (T californica)                                                          **1.59**      0.35          0.0530    zinc ion binding                                      0.0667
  NM_017458      MVP           major vault protein                                                                                                **1.52**      0.03          0.0635    cell cycle                                            0.0025
  AK025665       C22orf20      chromosome 22 open reading frame 20                                                                                **1.70**      0.03          0.0635    integral to membrane                                  0.6857

###### 

Two-sample comparison B-statistic analysis: transcripts abundant in 1 μM cisplatin treatments (relative to 25 μM transplatin treatments) for which a one-sample origin of differential expression could not be determined.

  Accession \#   Gene symbol     Full gene name                                                                                                  FOLD-change   B-statistic   P-value   Representative gene category                          EASE score
  -------------- --------------- --------------------------------------------------------------------------------------------------------------- ------------- ------------- --------- ----------------------------------------------------- ------------
  AF086149                       unknown                                                                                                         1.88          4.40          0.0055                                                          
  AL137705                       unknown                                                                                                         1.98          3.90          0.0072                                                          
  NM_007066      PKIG            protein kinase (cAMP-dependent, catalytic) inhibitor gamma                                                      2.04          3.80          0.0075    phosphate metabolism                                  0.7057
  NM_000861      HRH1            histamine receptor H1                                                                                           1.67          2.84          0.0153    response to pest/pathogen/parasite                    0.0021
  AL353944                       unknown                                                                                                         1.61          2.74          0.0167                                                          
  AK025758                       unknown                                                                                                         1.60          2.72          0.0167                                                          
  NM_002205      ITGA5           integrin, alpha 5 (fibronectin receptor, alpha polypeptide)                                                     1.92          2.70          0.0167    cell adhesion                                         0.3235
  AK024429       CLG             likely ortholog of mouse common-site lymphoma/leukemia GEF                                                      1.64          2.42          0.0194    response to external stimulus                         0.0075
  NM_005718      ARPC4           actin related protein 2/3 complex, subunit 4, 20kDa                                                             1.53          2.19          0.0208    cell motility                                         0.0688
  AB028949       KIAA1026        KIAA1026 protein                                                                                                1.72          2.17          0.0208    morphogenesis                                         0.0427
  NM_003946      NOL3            nucleolar protein 3 (apoptosis repress sor with CARD domain)                                                    1.76          2.15          0.0208    apoptosis                                             0.2968
  NM_014631      SH3MD1          SH3 multiple domains 1                                                                                          1.56          1.70          0.0275    cell communication                                    0.0279
  J03077         PSAP            prosaposin (variant Gaucher disease and variant meta chromatic leukodys trophy)                                 1.83          1.69          0.0275    sphingolipid metabolism                               0.2202
  AK026383                       unknown                                                                                                         1.54          1.59          0.0290                                                          
  NM_012098      ANGPTL2         angiopoietin-like 2                                                                                             1.71          1.57          0.0290    development                                           0.2095
  NM_000623      BDKRB2          bradykinin receptor B2                                                                                          1.66          1.15          0.0353    response to pest/pathogen/parasite                    0.0021
  AB028998       TENC1           tensin like C1 domain-containing phosphatase                                                                    2.00          1.15          0.0353    cell communication                                    0.0279
  NM_005127      CLECSF2         C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 2 (activation-induced)   1.53          1.14          0.0353    response to pest/pathogen/parasite                    0.0021
  NM_001878      CRABP2          cellular retinoic acid binding protein 2                                                                        1.47          1.12          0.0353    cell communication                                    0.0279
  NM_017720      STAP2           signal-transducing adaptor protein-2                                                                            1.50          1.11          0.0353    Cell communication                                    0.0279
  NM_001397      ECE1            endothelin converting enzyme 1                                                                                  1.46          1.00          0.0377    Cell communication                                    0.0279
  NM_014096                      unknown                                                                                                         1.63          0.96          0.0381                                                          
  NM_004604      STX4A           syntaxin 4A (placental)                                                                                         1.48          0.87          0.0395    cell growth and/or maintenance                        0.2968
  AF217967       PP1057          hypothetical protein PP1057                                                                                     1.69          0.78          0.0429                                                          
  NM_000075      CDK4            cyclin-dependent kinase 4                                                                                       1.49          0.75          0.0429    regulation of cell cycle                              0.0001
  NM_001975      ENO2            enolase 2, (gamma, neuronal)                                                                                    1.58          0.71          0.0432    energy derivation by oxidation of organic compounds   0.5979
  AF249898                       unknown                                                                                                         1.53          0.69          0.0432                                                          
  AK023787       FLJ13725        hypothetical protein FLJ13725                                                                                   1.60          0.69          0.0432                                                          
  M38449         TGFB1           transforming growth factor, beta 1 (Camurati-Engelmann disease)                                                 1.49          0.68          0.0432    regulation of cell cycle                              0.0001
  AF026816       ITPA            inosine triphosphatase (nucleoside triphosphate pyrophosphatase)                                                1.48          0.60          0.0454    nucleotide metabolism                                 0.6125
  NM_002547      OPHN1           oligophrenin 1                                                                                                  1.51          0.54          0.0469    cell communication                                    0.0279
  AK022226                       unknown                                                                                                         1.81          0.45          0.0491                                                          
  NM_002292      LAMB2           laminin, beta 2 (laminin S)                                                                                     1.58          0.41          0.0507    cell adhesion                                         0.3235
  AL049987                       unknown                                                                                                         1.42          0.39          0.0514                                                          
  AF086147                       unknown                                                                                                         1.39          0.36          0.0531                                                          
  NM_003714      STC2            stanniocalcin 2                                                                                                 1.55          0.35          0.0531    response to external stimulus                         0.0075
  NM_002960      S100A3          S100 calcium binding protein A3                                                                                 1.47          0.35          0.0535    pathogenesis/invasive growth                          1.0000
  NM_012266      DNAJB5          DnaJ (Hsp40) homolog, subfamily B, member 5                                                                     1.62          0.31          0.0535    response to stress                                    0.0356
  NM_017606      DKFZp434K1210   hypothetical protein DKFZp434K1210                                                                              1.46          0.30          0.0535                                                          
  NM_005238      ETS1            v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)                                                     1.58          0.23          0.0557    negative regulation of cell proliferation             0.0023
  NM_002192      INHBA           inhibin, beta A (activin A, activin AB alpha polypeptide)                                                       1.56          0.20          0.0569    regulation of cell cycle                              0.0001
  NM_014600      EHD3            EH-domain containing 3                                                                                          1.47          0.10          0.0608    cell growth and/or maintenance                        0.2968
  AB041269       LOC160313       keratin 19 pseudogene                                                                                           1.44          0.09          0.0613    cell growth and/or maintenance                        0.2968

###### Two-sample comparison B-statistic analysis: transcripts significantly up-regulated in 25 μM transplatin treatments (relative to both DMF (control) and 1 μM cisplatin treatments)

Transcripts are ranked in order of evidence for differential expression according to one-sample comparison B-statistics and corresponding P-values.

  Accession \#   Gene symbol   Full gene name                                    Fold-change   B-statistic   P-value   Representative gene category                                         EASE score
  -------------- ------------- ------------------------------------------------- ------------- ------------- --------- -------------------------------------------------------------------- ------------
  D17232                       unknown                                           1.98          2.363         0.0196                                                                         
  S81893                       unknown                                           1.83          2.273         0.0206                                                                         
  NM_003330      TXNRD1        thioredoxin reductase 1                           1.78          2.186         0.0208    heavy metal sensitivity/resistance                                   0.0115
  AK022848                     unknown                                           1.59          1.708         0.0275                                                                         
  NM_005953      MT2A          metallothionein 2A                                1.61          1.147         0.0353    heavy metal sensitivity/resistance                                   0.0115
  NM_002172      IFNA14        interferon, alpha 14                              1.57          1.027         0.0370    receptor binding                                                     0.1716
  NM_003535      HIST1H3J      histone 1, H3j                                    1.71          0.725         0.0429                                                                         
  NM_020313      LOC57019      hypothetical protein LOC57019                     1.44          0.575         0.0460    catalytic activity                                                   0.7398
  NM_020121      UGCGL2        UDP-glucose ceramide glucosyltransferase-like 2   1.59          0.503         0.0486    catalytic activity                                                   0.7398
  AK025004                     unknown                                           1.46          0.173         0.0581                                                                         
  AK025447       ZNF336        zinc finger protein 336                           1.43          0.125         0.0608    nucleobase\\, nucleoside\\, nucleotide and nucleic acid metabolism   0.1131
  AL080110       PAQR3         progestin and adipoQ receptor family member III   1.37          0.081         0.0613    integral to membrane                                                 0.7284

###### Two-sample comparison B-statistic analysis: transcripts significantly down-regulated in 1 μM cisplatin treatments (relative to both DMF (control) and 25 μM transplatin treatments)

Transcripts are ranked in order of evidence for differential expression according to one-sample comparison B-statistics and corresponding P-values.

  Accession \#   Gene symbol   Full gene name                                                                             Fold-change   B-statistic   P-value   Representative gene category                                    EASE score
  -------------- ------------- ------------------------------------------------------------------------------------------ ------------- ------------- --------- --------------------------------------------------------------- ------------
  NM_015885      PCF11         pre-mRNA cleavage complex II protein Pcf11                                                 1.94          5.319         0.0033    mRNA binding                                                    0.0286
  NM_003234      TFRC          transferrin receptor (p90, CD71)                                                           1.95          5.187         0.0033    transition metal ion homeostasis                                0.0481
  AF085846                     unknown                                                                                    1.83          4.802         0.0044                                                                    
  NM_005066      SFPQ          splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated)   1.86          4.310         0.0056    mRNA binding                                                    0.0286
  NM_002450      MT1L          metallothionein --1L                                                                       2.08          4.143         0.0058                                                                    
  NM_001945      DTR           diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor)     1.68          3.813         0.0075    positive regulation of cell proliferation                       0.0394
  U62823                       unknown                                                                                    1.79          2.616         0.0170                                                                    
  NM_004093      EFNB2         ephrin-B2                                                                                  2.06          2.245         0.0196    development                                                     0.1884
  NM_006910      RBBP6         retinoblastoma binding protein 6                                                           1.81          2.085         0.0214    cell proliferation                                              0.3191
  AK027074       KIAA1702      KIAA1702 protein                                                                           1.71          2.002         0.0218    phosphoenolpyruvate-dependent sugar phosphotransferase system   0.0425
  NM_016109      ANGPTL4       angiopoietin-like 4                                                                        1.80          1.561         0.0290                                                                    
  AK027174                     unknown                                                                                    1.97          1.362         0.0331                                                                    
  AL133111                     unknown                                                                                    1.57          1.181         0.0353                                                                    
  AB046797       ZSWIM6        zinc finger, SWIM domain containing 6                                                      1.54          1.149         0.0353    regulation of protein activity\\, epigenetic                    0.0370
  X73478         PPP2R4        protein phosphatase 2A, regulatory subunit B′ (PR 53)                                      1.62          1.104         0.0353    metabolism                                                      0.4686
  AK022171                     unknown                                                                                    2.36          0.947         0.0382                                                                    
  NM_005667      RNF103        ring finger protein 103                                                                    1.46          0.863         0.0395    nucleic acid binding                                            0.0727
  AK025835                     unknown                                                                                    1.44          0.728         0.0429                                                                    
  AK023939                     unknown                                                                                    2.25          0.592         0.0468                                                                    

###### 

Two-sample comparison B-statistic analysis: transcripts abundant in 25 μM transplatin treatments (relative to 1 μM cisplatin treatments) for which a one-sample origin of differential expression could not be determined.

  Accession \#   Gene symbol   Full gene name                                                    FOLD-change   B-statistic   P-value   Representative gene category                                         EASE score
  -------------- ------------- ----------------------------------------------------------------- ------------- ------------- --------- -------------------------------------------------------------------- ------------
  NM_003590      CUL3          cullin 3                                                          1.59          3.196         0.0114    positive regulation of cell proliferation                            0.0394
  Z36838                       unknown                                                           1.69          2.274         0.0206                                                                         
  AK024244       LOC284723     hypothetical protein LOC284723                                    1.92          2.201         0.0208                                                                         
  AL133074       TP53INP1      tumor protein p53 inducible nuclear protein 1                     1.64          2.065         0.0214                                                                         
  D28450         H2AFZ         H2A histone family, member Z                                      1.46          1.882         0.0240    nucleobase\\, nucleoside\\, nucleotide and nucleic acid metabolism   0.1131
  AK002085       LOC144438     hypothetical protein LOC144438                                    1.64          1.788         0.0257                                                                         
  NM_006620      HBS1L         HBS1-like (S. cerevisiae)                                         1.55          1.623         0.0290    protein biosynthesis                                                 0.7910
  AK025119                     unknown                                                           1.45          1.549         0.0290                                                                         
  AL110177                     unknown                                                           1.48          1.515         0.0292                                                                         
  NM_017761      PNRC2         proline-rich nuclear receptor coactivator 2                       1.55          1.510         0.0292    receptor activity                                                    0.7020
  AK026946       ARL6IP2       ADP-ribosylation-like factor 6 interacting protein 2              1.55          1.300         0.0338    response to external stimulus                                        0.8586
  NM_004219      PTTG1         pituitary tumor-transforming 1                                    1.40          1.077         0.0360    transcription\\ DNA-dependent                                        0.1145
  AK025697       LOC200933     hypothetical protein LOC200933                                    1.53          1.068         0.0369                                                                         
  NM_018514                    unknown                                                           1.62          1.005         0.0377                                                                         
  NM_003814      ADAM20        a disintegrin and metalloproteinase domain 20                     1.51          0.969         0.0381    sexual reproduction                                                  0.4054
  NM_014872      ZBTB5         zinc finger and BTB domain containing 5                           1.51          0.800         0.0419    transcription\\ DNA-dependent                                        0.1145
  NM_004894      C14orf2       chromosome 14 open reading frame 2                                1.44          0.726         0.0429                                                                         
  NM_006460      HIS1          HMBA-inducible                                                    1.61          0.644         0.0440    regulation of protein activity\\ epigenetic                          0.0370
  NM_006385      ZNF211        zinc finger protein 211                                           1.52          0.642         0.0440    transcription\\ DNA-dependent                                        0.1145
  U56725                       unknown                                                           1.48          0.597         0.0460                                                                         
  AK023371                     unknown                                                           1.78          0.588         0.0468                                                                         
  NM_002858      ABCD3         ATP-binding cassette, sub-family D (ALD), member 3                1.43          0.346         0.0531    cell growth and/or maintenance                                       0.3678
  NM_005461      MAFB          v-maf musculoaponeurotic fibrosarcoma oncogene homolog B(avian)   1.65          0.336         0.0535    transcription\\ DNA-dependent                                        0.1145
  NM_018138      FLJ10560      hypothetical protein FLJ10560                                     1.41          0.292         0.0535    carbohydrate transport                                               0.1018
  NM_004730      ETF1          eukaryotic translation termination factor 1                       1.46          0.261         0.0548    protein biosynthesis                                                 0.7910
  AK021725                     unknown                                                           1.70          0.185         0.0608                                                                         
  NM_003749      IRS2          insulin receptor substrate 2                                      1.67          0.116         0.0608    positive regulation of cell proliferation                            0.0394
  AF070617                     unknown                                                           1.52          0.083         0.0613                                                                         
  NM_006425      SLU7          step II splicing factor SLU7                                      1.44          0.057         0.0626    mRNA processing                                                      0.0548
  AK025020       AP1G1         adaptor-related protein complex1, gamma 1 subunit                 1.46          0.053         0.0622    endocytosis                                                          0.2677
  AL133611                     unknown                                                           1.64          0.052         0.0622                                                                         
  NM_017645      FAM29A        family with sequence similarity 29, member A                      1.58          0.049         0.0622                                                                         
  NM_004865      TBPL1         TBP-like 1                                                        1.44          0.036         0.0635    transcription\\ DNA-dependent                                        0.1145

###### Two-sample comparison B-statistic analysis: The first 30 most significantly over-represented gene categories among transcripts more abundant in 1 μM cisplatin treatments (relative to 25 μM transplatin treatments)

The number of transcripts in each gene category (List Hits) is also presented as a percentage of all the transcripts belonging to that category that were actually present on the microarray (Population Hits), and as a percentage of the 105 differentially expressed transcripts determined for that comparison (% Significant Transcripts). Categories are ranked in order of evidence for their over-representation among significant transcripts (EASE score).

  Rank   GO system            Gene category                                      List hits   Population hits   \% Population hits   \% Significant transcripts (Total = 105)   EASE score
  ------ -------------------- -------------------------------------------------- ----------- ----------------- -------------------- ------------------------------------------ --------------
  1      Biological Process   regulation of cell cycle                           12          362               3                    11                                         5.7 × 10^−5^
  2      Biological Process   regulation of cellular process                     9           311               3                    9                                          0.0018
  3      Biological Process   regulation of cell proliferation                   8           243               3                    8                                          0.0019
  4      Biological Process   response to pest/pathogen/parasite                 10          393               3                    10                                         0.0021
  5      Biological Process   negative regulation of cell proliferation          6           127               5                    6                                          0.0023
  6      Biological Process   cell cycle                                         13          653               2                    12                                         0.0025
  7      Biological Process   immune response                                    12          598               2                    11                                         0.0038
  8      Cellular Component   extracellular                                      17          1134              1                    16                                         0.0041
  9      Biological Process   cellular process                                   53          5588              1                    50                                         0.0065
  10     Biological Process   response to wounding                               7           231               3                    7                                          0.0066
  11     Biological Process   response to external stimulus                      17          1145              1                    16                                         0.0075
  12     Biological Process   defense response                                   12          657               2                    11                                         0.0077
  13     Biological Process   cell proliferation                                 15          988               2                    14                                         0.0112
  14     Cellular Component   extracellular matrix                               7           288               2                    7                                          0.0146
  15     Biological Process   response to biotic stimulus                        12          720               2                    11                                         0.0147
  16     Biological Process   cell communication                                 29          2744              1                    28                                         0.0279
  17     Biological Process   regulation of mitotic cell cycle                   2           4                 50                   2                                          0.0288
  18     Biological Process   inflammatory response                              5           160               3                    5                                          0.0291
  19     Biological Process   signal transduction                                24          2167              1                    23                                         0.0325
  20     Biological Process   innate immune response                             5           166               3                    5                                          0.0327
  21     Molecular Function   cytokine activity                                  5           180               3                    5                                          0.0329
  22     Biological Process   cell-cell signaling                                9           515               2                    9                                          0.0332
  23     Biological Process   response to stress                                 11          721               2                    10                                         0.0356
  24     Molecular Function   receptor binding                                   8           472               2                    8                                          0.0388
  25     Biological Process   morphogenesis                                      13          956               1                    12                                         0.0427
  26     Molecular Function   transforming growth factor-beta receptor binding   2           7                 29                   2                                          0.0462
  27     Biological Process   cell surface receptor linked signal transduction   13          968               1                    12                                         0.0463
  28     Biological Process   cell cycle arrest                                  3           50                6                    3                                          0.0512
  29     Molecular Function   zinc ion binding                                   6           324               2                    6                                          0.0667
  30     Biological Process   cell motility                                      6           302               2                    6                                          0.0688

###### Two-sample comparison B-statistic analysis: The first 30 most significantly over-represented gene categories among transcripts more abundant in 25 μM transplatin treatments (relative to 1 μM cisplatin treatments)

The number of transcripts in each gene category (List Hits) is also presented as a percentage of all the transcripts belonging to that category that were actually present on the microarray (Population Hits), and as a percentage of the 64 differentially expressed transcripts determined for that comparison (% Significant Transcripts). Categories are ranked in order of evidence for their over-representation among significant transcripts (EASE score).

  Rank   GO system            Gene category                                                        List hits   Population hits   \% Population hits   \% Significant transcripts (Total = 64)   EASE score
  ------ -------------------- -------------------------------------------------------------------- ----------- ----------------- -------------------- ----------------------------------------- ------------
  1      Biological Process   heavy metal sensitivity/resistance                                   2           4                 50.0                 3                                         0.0115
  2      Cellular Component   intracellular                                                        27          6576              0.4                  42                                        0.0181
  3      Molecular Function   mRNA binding                                                         3           87                3.4                  5                                         0.0286
  4      Biological Process   regulation of protein activity\\, epigenetic                         2           13                15.4                 3                                         0.0370
  5      Biological Process   positive regulation of cell proliferation                            3           109               2.8                  5                                         0.0394
  6      Biological Process   phosphoenolpyruvate-dependent sugar phosphotransferase system        2           15                13.3                 3                                         0.0425
  7      Biological Process   transition metal ion homeostasis                                     2           17                11.8                 3                                         0.0481
  8      Biological Process   mRNA processing                                                      3           131               2.3                  5                                         0.0548
  9      Biological Process   mRNA metabolism                                                      3           146               2.1                  5                                         0.0663
  10     Molecular Function   nucleic acid binding                                                 13          2586              0.5                  20                                        0.0727
  11     Cellular Component   nucleus                                                              13          2675              0.5                  20                                        0.0882
  12     Biological Process   carbohydrate transport                                               2           37                5.4                  3                                         0.1018
  13     Molecular Function   binding                                                              24          6252              0.4                  38                                        0.1078
  14     Biological Process   nucleobase\\, nucleoside\\, nucleotide and nucleic acid metabolism   12          2620              0.5                  19                                        0.1131
  15     Biological Process   transcription\\, DNA-dependent                                       9           1730              0.5                  14                                        0.1145
  16     Biological Process   di-\\, tri-valent inorganic cation homeostasis                       2           43                4.7                  3                                         0.1173
  17     Molecular Function   antioxidant activity                                                 2           41                4.9                  3                                         0.1176
  18     Molecular Function   DNA binding                                                          10          1944              0.5                  16                                        0.1219
  19     Molecular Function   sugar porter activity                                                2           44                4.5                  3                                         0.1256
  20     Biological Process   metal ion homeostasis                                                2           48                4.2                  3                                         0.1301
  21     Molecular Function   carbohydrate transporter activity                                    2           50                4.0                  3                                         0.1415
  22     Molecular Function   RNA binding                                                          4           437               0.9                  6                                         0.1460
  23     Biological Process   regulation of cell proliferation                                     3           243               1.2                  5                                         0.1554
  24     Biological Process   cation homeostasis                                                   2           63                3.2                  3                                         0.1673
  25     Molecular Function   receptor binding                                                     4           472               0.8                  6                                         0.1716
  26     Molecular Function   pre-mRNA splicing factor activity                                    2           63                3.2                  3                                         0.1750
  27     Biological Process   regulation of gene expression\\, epigenetic                          2           69                2.9                  3                                         0.1817
  28     Biological Process   cell ion homeostasis                                                 2           70                2.9                  3                                         0.1841
  29     Biological Process   development                                                          8           1646              0.5                  13                                        0.1884
  30     Biological Process   regulation of transcription\\, DNA-dependent                         8           1660              0.5                  13                                        0.1942
